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ABSTRACT 
 
BACKGROUND: Procedural sedation and analgesia (PSA) is generally safe, and 
often necessary to successfully undertake dental procedures in children. Providing 
PSA in dental rooms avoids expenses generated by having to perform procedures in 
operating theatres, but this must not be done at the cost of patient safety. Although 
rare, severe adverse events that occur are usually preventable. Death and 
permanent neurological injury are unacceptable outcomes for healthy children being 
sedated for minor procedures. 
 
OBJECTIVES: The objectives of this study were to determine the proportion of 
dental practitioners making use of paediatric dental chair PSA in Gauteng, describe 
their PSA practice, and to determine adherence to recommended safety standards. 
 
METHOD: A prospective, contextual, descriptive survey study design was used. 
Two-hundred and thirteen Gauteng-based dental practitioners were randomly 
selected from the list of 1152 practitioners listed on the South African Dental 
Association’s website and contacted telephonically to determine whether they offer 
paediatric dental chair PSA. Practitioners offering PSA were then sent an email 
containing a link to a web-based data collection sheet assessing various aspects of 
their PSA practice. 
 
RESULTS: Ninety-four of 213 dental practitioners contacted provide PSA to children 
(44.13%; 95% CI, 0.37-0.51). Fifty-two of the 94 practitioners completed the data 
collection sheet. The dental practitioner is most commonly responsible for 
administering PSA (45.83% of dental practices), with anaesthetists or medical 
practitioners also performing this task in some practices.  
 
The modalities of PSA provided vary between dental practices. Procedures are 
usually performed under minimal or moderate sedation (used in 56.25% and 52.08% 
of practices respectively), although deep sedation and general anaesthesia are also 
provided in dental rooms (10.42% and 2.08% respectively). Midazolam, nitrous oxide 
and propofol are the most popular agents used for sedation. Sedative agents are 
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administered mainly via the oral, intravenous and inhalational routes (52.08%, 
45.83%, and 41.67% of practices respectively). Most PSA providers (68.75%) 
administer a combination of two or more sedative agents.   
 
Of the dental practitioners responsible for administering PSA, 54.55% have had 
sedation training, 90% have attended a Basic Life Support course, 10% have 
attended Advanced Paediatric Life Support or Paediatric Advanced Life Support 
courses, and 20% are aware of the South African Society of Anaesthesiologists’ 
guidelines for the safe use of procedural sedation and analgesia for diagnostic and 
therapeutic procedures in children. Most respondents (81.82%) indicated that they 
are interested in attending a sedation course. 
 
Patients are mainly ASA physical status 1 and 2 and fall mainly into the 1 to 5 year 
old age group. However, there are dental practices that offer PSA to infants and ASA 
3 and 4 patients. Fasting recommendations vary, with some patients being 
inadequately starved and others being inappropriately starved for 8 hours or longer. 
 
Of the dental practices that provide sedation, 41.30% do not use any monitoring 
equipment, 43.18% do not keep any of the recommended emergency drugs in stock 
and 19.57% do not have any emergency equipment available. 
 
Reported adverse events during dental chair PSA are rare, with no major adverse 
event reported in this study. 
 
CONCLUSION: Paediatric dental chair PSA is offered by 44.13% of dental 
practitioners interviewed in Gauteng. The modalities of PSA provided vary between 
dental practices. Many facilities do not adhere to recommended safety standards for 
prevention and management of adverse events. Particular areas of concern are the 
high number of practices in which no monitoring equipment, emergency equipment, 
or emergency drugs are available. There is however an interest in sedation training 
among dental practitioners. 
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CHAPTER ONE 
OVERVIEW OF THE STUDY 
 
1.1 Introduction 
In this chapter the following will be discussed: a background to this study; the 
problem statement, aim and objectives of the study; research assumptions; 
demarcation of the study field; ethical considerations; a summary of the research 
methodology; the significance of the study; and validity and reliability of the study. 
 
1.2 Background 
Procedural sedation and analgesia (PSA) provided in dental rooms is cost-effective 
as it avoids extra expenses generated by having to perform dental procedures in 
operating theatres. It allows the dentist to practise in the familiarity of his or her own 
rooms (1), and overcomes the need to rely on the limited availability of 
anaesthesiologists. 
 
Dental chair PSA should not, however, be performed at the cost of patient safety. An 
American-based critical incident analysis of 118 reported serious adverse paediatric 
sedation events (more than 80% of which began with some respiratory compromise) 
revealed a final outcome of death or permanent neurological deficit in 92.8% of these 
cases in out-of-hospital facilities versus 37.2% of hospital-based cases. Drug 
interactions, drug overdose, inadequate monitoring, inadequate resuscitation, 
inadequate medical evaluation and premature discharge were found to be the most 
common contributory causes of these adverse sedation events. (2) 
 
Death and permanent neurological injury are unacceptable outcomes for healthy 
children sedated for minor procedures. This suggests the need to adopt guidelines 
which could reduce the risk of adverse events associated with PSA (3). The South 
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African Society of Anaesthesiologists (SASA) published guidelines for the safe use 
of procedural sedation and analgesia for diagnostic and therapeutic procedures in 
children in 2010 (SASA PSA guidelines) (4). The aim of the guideline is to provide a 
reference to enable practitioners to act within a framework that ensures patient 
safety and the successful performance of procedures. They are intended for use by 
all medical practitioners, including dentists, to provide safe sedation, analgesia and 
anxiolysis in all environments and to provide guidance on patient selection, 
recommended drugs and dosages, equipment, monitoring, documentation and 
discharge criteria. (4) 
 
1.3 Problem statement 
PSA is generally safe, and is often necessary to successfully undertake dental 
procedures in children. Severe adverse events and outcomes that occur are mostly 
preventable. The guidelines formulated by SASA serve to provide a framework for 
practitioners to safely provide PSA to children in all environments (4). 
 
No data could be identified as to how many dental practices in Gauteng make use of 
PSA and how many sedation practitioners are aware of the available SASA PSA 
guidelines (4). Practising outside the framework of these guidelines may place 
children at increased risk of adverse events and outcomes. 
 
1.4.1 Aim 
The aim of this study was to determine the proportion of dental practitioners making 
use of paediatric dental chair PSA in Gauteng and to describe paediatric dental chair 
PSA practice, awareness of the 2010 SASA PSA guidelines (4), and adherence to 
the guidelines.  
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1.4.2 Objectives 
The objectives of this study were to: 
 determine the proportion of dental practitioners in Gauteng that utilise paediatric 
dental chair PSA;  identify the professional category of person primarily responsible for 
administering PSA;  describe the modalities of PSA administered in dental rooms  
o depth of sedation 
o drugs used 
o number of sedative agents used in combination 
o routes of administration;  describe the sedation and resuscitation training of PSA providers;  determine adherence to recommended safety standards for prevention of 
adverse events 
o age groups of children sedated 
o American Society of Anesthesiologists (ASA) physical status 
o pre-sedation assessment and informed consent 
o fasting 
o person responsible for patient monitoring 
o monitoring equipment 
o level of consciousness or depth of sedation monitoring 
o recovery;  determine adherence to recommended safety standards for management of 
adverse events 
o emergency drugs 
o emergency equipment;  determine the occurrence of complications of PSA.  
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1.5 Research assumptions 
The following definitions were used in this report: 
Child or paediatric patient: An individual 12 years or younger falls into this 
category for the purpose of this study. A patient in this report refers to a child. 
 
Dental practice or practice: Refers to the dental rooms. The dental practitioner 
may or may not be the person responsible for PSA administration in this practice.                              
 
Dental practitioner: The person who performs the dental procedure, but may or 
may not be the person responsible for PSA administration in a particular dental 
practice. 
 
Procedural sedation and analgesia (PSA): The alleviation of pain or discomfort 
and/or a drug-induced altered state of consciousness ranging from minimal to deep 
sedation, provided for a variety of diagnostic and therapeutic procedures (4). 
 
SurveyMonkey™ (5): A commercial online survey site which facilitates the creation 
of surveys. It hosts the survey, collects results and analyses data. 
 
As reference is drawn to the SASA PSA guidelines (4), the following definitions are 
as described in the guidelines: 
Minimal sedation and anxiolysis: “Minimal sedation is a drug-induced state during 
which the patient responds normally to verbal commands. Cognitive function may be 
impaired, but ventilatory and cardiovascular functions are unaffected.” 
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Moderate sedation and analgesia: “Moderate sedation is a drug-induced 
depression of consciousness during which the patient responds purposefully to 
verbal commands, either alone or accompanied by light, tactile stimulation. No 
interventions are required to maintain a patent airway and spontaneous ventilation is 
adequate.” 
 
Deep sedation and analgesia: “Deep sedation is a drug-induced depression of 
consciousness during which the patient cannot easily be roused, but may respond 
purposefully following repeated or painful stimulation. (Reflex withdrawal from a 
painful stimulus is not considered a purposeful response.) The patient may require 
assistance in maintaining a patent airway and spontaneous ventilation may be 
inadequate. Cardiovascular function is usually maintained.” 
 
General anaesthesia: “General anaesthesia is a drug-induced loss of 
consciousness during which patients cannot be roused, even by painful stimulation. 
The ability to maintain independent ventilatory function is impaired. Patients require 
assistance in maintaining a patent airway, and positive pressure ventilation may be 
required because of depressed spontaneous ventilation or drug-induced depression 
of neuromuscular function. Cardiovascular function may be impaired.” 
 
The distinction between the levels of sedation was initially made for the purpose of 
describing appropriate physiological monitoring. One should be aware that, 
regardless of the intended level or route of drug administration, sedation represents 
a continuum, with a patient easily moving from a light to deeper level (6). 
 
The SASA PSA guidelines (4) also differentiate between two sedation techniques: 
 Simple or basic sedation: “Simple/basic sedation is induced by a single agent 
and not a combination of single agents, for example: 
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o Oral, transmucosal or rectal drugs, e.g. a small dose of an oral 
benzodiazepine; or  
o Inhalation of nitrous oxide (N2O) in at least 50% oxygen. 
Sedation can no longer be considered simple or basic once additional agents 
become necessary, and the depth of sedation may not be advanced unless the 
patient is fasted.” 
 
 Advanced sedation: “Advanced sedation is induced by one of the following 
techniques: 
o Any combination of drugs, administered by any route; or 
o Any sedation administered by the intravenous route, using bolus or infusion 
techniques; or 
o Any inhalational sedation (e.g. sevoflurane), with the exception of N2O used 
as the sole agent in a concentration of less than 50% in oxygen. 
Advanced sedation can include both dissociative and nondissociative 
techniques.” 
 
American Society of Anesthesiologists (ASA) physical status classification (7): 
 “ASA Physical Status 1 - A normal healthy patient  ASA Physical Status 2 - A patient with mild systemic disease  ASA Physical Status 3 - A patient with severe systemic disease  ASA Physical Status 4 - A patient with severe systemic disease that is a 
constant threat to life  ASA Physical Status 5 - A moribund patient who is not expected to survive 
without the operation  ASA Physical Status 6 - A declared brain-dead patient whose organs are being 
removed for donor purposes” 
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1.6 Demarcation of study field 
This study was conducted in the Gauteng Province and included the dental practices 
of members of the South African Dental Association (SADA) practising in Gauteng 
(8). SADA represents the vast majority of active dentists in South Africa and is the 
most relied upon body regarding all aspects of dental practice in the country (9). 
Currently SADA lists 1152 Gauteng-based members on its website (8). 
 
1.7 Ethical considerations 
Approval to conduct this study was obtained from the Postgraduate Committee 
(Appendix 1) and the Human Research Ethics Committee (Medical) (HREC) 
(Appendix 2) of the University of the Witwatersrand. 
 
This study did not involve any drug or therapeutic management and no patient was 
directly involved. It was conducted in accordance with the Declaration of Helsinki 
(10) and the South African Good Clinical Practice Guidelines (11). 
 
1.8 Research methodology 
1.8.1 Study design 
A prospective, contextual, descriptive survey study design was used. 
 
1.8.2 Study population 
Qualified dental practitioners who were listed on the SADA website and practising in 
Gauteng formed the population group studied (8).  
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1.8.3 Study sample 
1.8.3.1 Sample size 
The names and contact numbers of 1152 Gauteng-based SADA members were 
listed on the SADA website (8). Two hundred dental practitioners were invited to 
participate in the study. This figure (n=200) would be increased following initial data 
collection if necessary, until a minimum of 20 completed data collection sheets were 
received. 
 
1.8.3.2 Sampling method 
A simple random sampling method was used in this study. 
 
1.8.3.3 Inclusion and exclusion criteria 
All Gauteng-based dental practitioners who were members of SADA and listed on 
the SADA website on 23 June 2012 were included in the study (8). Members who 
declined to participate were excluded. 
 
1.8.4 Data collection 
A web-based data collection sheet (Appendix 3) was designed for data collection 
using SurveyMonkey™. Prior to developing the data collection sheet, a review of the 
literature was done in order to identify the potential safety pitfalls in the field of 
paediatric dental chair sedation. The SASA PSA guidelines (4) served as the main 
reference point for the development of the data collection sheet, which was reviewed 
by three anaesthesiologists in order to ensure accuracy and validity. 
 
1.8.5 Data analysis 
Incoming data was analysed as it was received by SurveyMonkey™, the website 
hosting the data collection sheet. Descriptive statistics using frequencies and 
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percentages were used to analyse the data. A proportion and confidence interval 
were determined with support from a biostatistician. 
 
1.9 Significance of study 
The World Health Organisation (WHO) has identified the need for research to 
improve patient safety as a global priority (12). Comparing data with recommended 
safety standards has identified areas of concern, and may serve as a guide to 
developing measures that will enhance safety during paediatric dental chair 
sedation. 
 
No study could be identified that determined the proportion of practices providing 
dental chair PSA or evaluated dental chair PSA practice in a South African setting. 
The 2010 SASA PSA guidelines (4) were the first of its kind to be published in this 
country. A review of the literature revealed flaws in safety standards in an American 
setting prior to the development of sedation guidelines and an improvement in 
outcomes thereafter. 
 
This study determined the proportion of dental practitioners contacted in the Gauteng 
Province that utilise paediatric dental chair PSA and their awareness of the SASA 
PSA guidelines (4). It helped to shed light on the professional category of person 
responsible for patients during and after PSA, patient selection and assessment, 
modalities of sedation used, patient monitoring, the availability of emergency drugs 
and equipment, the resuscitation training of practitioners, and safety issues 
pertaining to the recovery area and discharge. The study also served to identify the 
need for training in the field of paediatric dental chair PSA. 
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1.10 Validity and reliability summary 
Validity and reliability of the study and data collection sheet were ensured by the 
following: 
 A representative sampling frame comprising SADA members;  Randomisation of the sampling frame to minimise sampling bias;  Instruments used and variables assessed in similar studies were used as a 
guide in the development of the data collection sheet, which was then reviewed 
by three experts in the field;  An anonymous, short and concise data collection sheet. 
 
1.11 Project outline 
This report consists of five chapters: chapter one represents an overview of this 
research report; chapter two is a review of the current relevant literature; chapter 
three covers the research methodology and study considerations in more detail; 
chapter four presents the results and discussion; chapter five summarises the study, 
addresses its limitations, makes recommendations and presents a conclusion. 
 
1.12 Summary 
In this chapter the following was addressed: a background to this study; the problem 
statement, aim and objectives of the study; research assumptions; demarcation of 
the study field; ethical considerations; a summary of the research methodology; the 
significance of the study; and validity and reliability of the study. The next chapter 
comprises a review of the current relevant literature. 
 
 
 
 
 
11 
 
CHAPTER TWO 
LITERATURE REVIEW 
 
2.1 Introduction 
In this chapter the literature relevant to this study will be reviewed. Firstly, a 
background to the development of sedation guidelines will be provided, followed by a 
discussion about the vulnerability of children to adverse sedation outcomes. The 
pharmacology of various PSA agents will be summarised and the risks associated 
with sedation considered thereafter. The 2010 SASA PSA guidelines (4) will then be 
discussed in detail, followed by an overview of the Society of Sedation Practitioners 
of South Africa. A similar study auditing dental chair sedation will then be reviewed. 
Lastly, the benefits of applying guidelines to the practice of sedation will be 
considered. 
 
2.2 Background 
“Every year, tens of millions of patients worldwide suffer disabling injuries or death 
due to unsafe medical care.” (Sir Liam Donaldson, Chair, WHO Patient Safety). Little 
is known about the burden of unsafe care in out-of-hospital settings, where the bulk 
of health care is delivered. The WHO has identified the need for research aimed at 
improving patient safety as a priority, especially in developing and transitional 
countries. (12) 
 
Although most people find dental procedures unpleasant, the majority can be 
performed under local anaesthesia alone. Sedation is needed in dentistry to facilitate 
treatment of anxious or phobic patients, enable unpleasant procedures to be 
performed without distress, and to avoid the need for general anaesthesia. Despite 
PSA making healthcare procedures more acceptable to patients, it still carries the 
potential to cause life-threatening complications. (13) 
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Dental chair sedation and anaesthesia dates back to the discovery of N2O in 1844 
(14). In the early 1980s, within a one year period three healthy American children 
suffered adverse events after being sedated for dental procedures (the details of 
these adverse events are not elaborated on in the literature). This spurred the 
development of the first sedation guidelines. (15) The Committee on Drugs (COD) of 
the American Academy of Pediatrics (AAP) was concerned about the continued 
appearance of reports, almost always from non-medical sources (word of mouth, 
newspapers), of morbidity and mortality in children after sedation for seemingly 
harmless procedures (16). In 1983 case reports were published (discussed in more 
detail below) in the United States of a number of deaths in the dental office, and for 
this reason the COD worked closely with its dental colleagues to develop the 
guidelines for the elective use of conscious sedation, deep sedation, and general 
anesthesia in pediatric patients (16-19). The first sedation guidelines thus contained 
specific reference to dentists (17). 
 
The guidelines provided a framework for the entire sedation process, from patient 
selection and evaluation to the recovery area and discharge. It also discussed 
fasting, informed consent, documentation, patient monitoring, emergency equipment 
and drugs, and recommended a safe approach to patient care at the different depths 
of sedation (16). It then became apparent that sedation was provided in a variety of 
settings by individuals with different degrees of expertise and when the guidelines 
were updated in 1992, reference to dentistry was removed since the COD did not 
want to single out one speciality (6, 17). Since then various professional bodies have 
developed their own paediatric sedation guidelines or revised existing ones (4, 6, 20-
25). Although they may differ in their content, they share the same common theme of 
patient safety. 
 
2.3 Why focus on children? 
Paediatric patients require sedation or anaesthesia for dental procedures more often 
than adults and are at a higher risk of adverse events than any other patient 
subgroup (26). Sedation in children is different to sedation in adults. In children 
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sedation is usually administered to control behaviour in order to achieve optimal 
conditions for the completion of a procedure. Behaviour control and cooperation 
depends on the individual’s developmental and chronological age. (20) Importantly, 
children are anatomically and physiologically different to adults, and at higher risk for 
life-threatening hypoxia as a result of both respiratory depression and airway 
obstruction (26, 27). Children younger than six years of age and those with 
developmental delay often require deeper levels of sedation to control their 
behaviour and are particularly vulnerable to sedating medications’ effects on their 
respiratory drive, airway patency, and protective reflexes (20). Children also tend to 
pass into a level of sedation deeper than intended (3, 20, 28). This is associated with 
increased risks, which are discussed in more detail later in the report. 
 
2.4 Pharmacology 
Sedation practitioners should understand the pharmacodynamics and 
pharmacokinetics of the drugs they use. There should be a uniform level of vigilance 
regardless of drug dose, class or route of administration. Practitioners must be 
equipped with the skills and instruments needed to manage an adverse drug event 
should it occur. 
 
The potential for adverse outcomes is significantly increased when three or more 
drugs with sedative properties are combined (4, 20, 29). A sedative has the potential 
to cause respiratory depression regardless of its route of administration (17, 29), and 
even medication which is considered “safe” can depress the patient’s ability to 
respond normally to airway obstruction once the drug depresses the central nervous 
system (30, 31). A lack of stimulation, delayed drug elimination following non-
intravenous administration (21), and the use of long-acting agents (4, 29) may lead 
to residual sedation and complications during the recovery period and after 
discharge. 
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In an analysis of 95 paediatric sedation adverse events, Cote et al. (29) did not find 
any correlation between a specific drug class and adverse outcome. In some cases, 
adverse events occurred despite drugs being administered within recommended 
dosing ranges. Negative outcomes also took place at home or in a car on the way to 
the facility after drugs were administered by non-medically trained persons at home. 
(29) 
 
The relevant pharmacology of some of the agents used during PSA and the potential 
problems associated with their use will briefly be outlined. This will put the adverse 
events discussed later in the report into perspective. This section is not aimed at 
providing an in-depth discussion of the pharmacodynamics and pharmacokinetics of 
the drugs listed. 
 
2.4.1 Inhalational agent: nitrous oxide 
Inhaled N2O provides sedation and mild analgesia (32). It is available in its pure form 
or may be pre-mixed with oxygen in a 1:1 ratio (Entonox®) (4). In older children it 
may be safely administered via a self-held demand-valve mask which is only 
activated when the child inspires (4, 32). A continuous flow system is needed in 
children unable to operate a demand-valve (4). The SASA PSA guidelines (4) 
recommend a dose of 50% N2O mixed with oxygen, with higher concentrations 
placing the child in a state of moderate, rather than minimal, sedation. The 
implications in terms of monitoring and adverse events attached to depth of sedation 
are discussed later in this report. Other sources describe N2O concentrations of up to 
70% with preservation of haemodynamic status, spontaneous breathing and 
protective airway reflexes (32).  
 
Although N2O possesses analgesic activity, it usually needs to be supplemented with 
an opioid and or local anaesthetic agent (32). It is generally considered a safe agent, 
but when combined with any other depressing medication, even in normal dosing 
ranges, this may lead to a state of deep sedation or general anaesthesia (29), with 
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ensuing respiratory depression and or loss of protective airway reflexes. Minor 
adverse effects of N2O include nausea, dizziness, voice change, euphoria and 
laughter (32). 
 
Nitrous oxide should not be used in certain patients. It diffuses into air-filled cavities 
and should be avoided in patients with closed-space diseases, e.g. suspected bowel 
obstruction, pneumothorax or middle ear disease (4, 32). Children with 
cardiovascular and respiratory disease should not be given N2O as it may alter the 
response to hypoxia or cause harmful haemodynamic changes. The use of N2O is 
therefore only recommended in ASA 1 and 2 patients. (4) 
 
None of the other inhalational anaesthetic agents (e.g. sevoflurane) are described in 
the SASA PSA guidelines (4) and will not be discussed here. These agents 
necessitate administration by specialised equipment and are not compatible with the 
typical office situation (33). 
 
2.4.2 Sedative-hypnotics 
The following agents will be discussed: chloral hydrate, barbiturates, 
benzodiazepines and propofol. 
 Chloral hydrate: 
Chloral hydrate is a pure sedative-hypnotic drug without analgesic properties and its 
use is recommended for non-painful procedures only (4, 32). It is generally a safe 
drug in the recommended dosing range, but respiratory depression and airway 
obstruction may occur at higher doses (above 75 mg/kg) or when combined with 
other depressant drugs. Combining chloral hydrate with other agents is thus not 
recommended. (4) The duration of action (DOA) of chloral hydrate is 60 to 150 
minutes with a possibility of motor imbalance and agitation persisting for several 
hours thereafter (32). The need for prolonged monitoring makes chloral hydrate a 
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poor choice for dental chair sedation. Its sedative effects are also unreliable in 
children over three years of age. (4) 
 
 Barbiturates: 
Drugs in this class include pentobarbital, methohexital and thiopental. They usually 
produce deep sedation (or general anaesthesia), hypnosis and amnesia and also 
have anticonvulsant activity (32). These drugs can cause potent respiratory 
depression and hypotension (32) and aren’t listed in the SASA PSA guidelines (4). 
 
 Benzodiazepines: 
Midazolam and diazepam are among the drugs in this class and possess anxiolytic, 
amnestic, sedative, hypnotic, and anticonvulsant properties. They do not have 
analgesic properties and are commonly used with opioids, posing a much greater 
risk for apnoea as their combined effects are not just additive but synergistic. (32) 
Besides respiratory depression, benzodiazepines can also cause a loss of upper 
airway muscle tone with subsequent airway obstruction (4). Mild cardiovascular 
depression with hypotension may also occur (32). Flumazenil should be available as 
a benzodiazepine antagonist.  
 
Diazepam was first used for PSA, but because of its shorter DOA and multiple routes 
of administration midazolam is now the benzodiazepine of choice (32). It can be 
administered via the oral, sublingual, intravenous, rectal, and intranasal routes with 
the DOA ranging from 20 to 120 minutes depending on route of administration (4). 
Patients require continuous monitoring irrespective of route of administration as 
respiratory depression can arise via any of these routes (32). A series of deaths from 
undetected apnoea were reported shortly after the release of midazolam and before 
the use of continuous interactive and mechanical monitoring, highlighting the 
importance of such monitoring (29, 32, 34). 
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Practitioners should be aware of the possibility of a paradoxical reaction. This is 
characterised by inconsolable crying, combativeness, disorientation, agitation and 
restlessness, and has been reported in up to 15% of children receiving midazolam.  
(32) There may be a tendency to then give additional doses of midazolam in an 
attempt to control the child, which will exacerbate the symptoms and eventually lead 
to a loss of consciousness and respiratory depression (4). 
 
 Propofol: 
Propofol is a potent induction agent with a rapid onset and short DOA (15 minutes), 
all desirable characteristics for PSA (32). It is administered intravenously either as a 
bolus or a continuous infusion (4). 
 
Although propofol is an effective drug, it has a narrow margin of safety. Deep 
sedation or general anaesthesia with subsequent airway obstruction and apnoea can 
occur rapidly (4, 21). Hypotension may also result (21, 32). The SASA PSA 
guidelines (4) recommend that propofol should only be administered by an 
experienced sedationist with anaesthetic training and paediatric airway management 
skills. Use of the drug outside the operating theatre is controversial. (4) 
 
2.4.3 Dissociative sedative: ketamine 
Cortical dissociation is characterised by profound analgesia, sedation and amnesia. 
This allows painful procedures to be performed more effectively than with other PSA 
drugs and with an excellent safety profile. (32) Ketamine can be administered via the 
oral, intravenous, intramuscular or rectal route. Analgesic effects are achieved at 
subhypnotic doses. (4) 
 
Ketamine may cause unwanted non-purposeful movements. Compared with other 
anaesthetic agents, patients have a relative preservation of protective airway 
reflexes and muscle tone, which may be lost with large doses. (4) Spontaneous 
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respiration is usually preserved (32). Ketamine causes an increased production of 
tracheobronchial secretions and saliva, which can predispose patients to 
laryngospasm (4). The SASA PSA guidelines (4) recommend prophylactic co-
administration of an antisialogogue (atropine or glycopyrrolate) to diminish 
secretions. Furthermore, because of its dissociative properties, the usual clinical 
indications of sedation depth may not apply (e.g. a child’s eyes may be open despite 
being in a state of deep sedation) (21). 
 
Tachycardia and hypertension associated with the sympathomimetic action of 
ketamine are not usually seen at sedative doses, and emergence delirium is mild 
and less common in children than in adults (4). 
 
2.4.4 Analgesics 
Analgesics will be discussed in the following categories: opioids, simple analgesics 
and local anaesthetics. 
 Opioids: 
Opioids are primarily analgesic agents that can induce varying degrees of sedation 
as well as respiratory and cardiac depression. The opioid antagonist naloxone 
should be available. (4) 
 
Fentanyl and alfentanil are potent short-acting agents, with a DOA of up to one hour 
for fentanyl (dose-dependent) and five minutes for alfentanil. Both are administered 
intravenously, while fentanyl can also be given via the oral or transmucosal route. 
The SASA PSA guidelines (4) suggest that practitioners administering these agents 
should be experienced sedationists with airway management skills due to the 
significant potential for respiratory depression, particularly when used in combination 
with other respiratory depressant drugs. (4) 
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Tilidine is an intermediate-acting opioid (DOA of 4 to 6 hours) available in droplet 
form for sublingual administration (4). 
 
Fentanyl, alfentanil and tilidine are the only opioids discussed in the SASA PSA 
guidelines (4). Other agents include morphine, meperidine, remifentanil and 
alphaprodine. Morphine and meperidine are long-acting agents and may necessitate 
prolonged post-procedure monitoring. Remifentanil is currently not recommended for 
PSA in children (4). It is a potent short-acting opioid with a significant potential for 
respiratory depression. Alphaprodine is no longer manufactured (29), but is 
mentioned here as it is appears later in the report. 
 
 Simple analgesics: 
Paracetamol and non-steroidal anti-inflammatory drugs appear in this category in the 
SASA PSA guidelines (4). They have no sedative effects (29). 
 
 Local anaesthetics: 
Local anaesthetics reduce the need for other PSA agents and should be used 
whenever possible. Practitioners using these drugs must be aware of their maximum 
safe doses, as toxicity could potentially be fatal (35). Local anaesthetics are 
membrane depressants, and excessive doses may lead to cardiovascular, 
respiratory and central nervous system depression. The SASA PSA guidelines (4) 
list the maximum safe dose of bupivacaine (2.5 mg/kg) and lignocaine (3 mg/kg and 
7 mg/kg if adrenaline is added). If agents are combined, it should be done with 
caution as toxicity is additive. (4) 
 
There are other sedating agents listed in the SASA PSA guidelines (4) which will not 
be discussed in detail here. These include trimeprazine (a phenothiazine derivative) 
and droperidol (a butyrophenone with antiemetic properties), which are not 
recommended for outpatient procedures due to their long DOA. Dexmedetomidine 
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(an alpha-2 antagonist) should only be used by practitioners with anaesthetic training 
and experienced in paediatric sedation. (4) 
 
2.4.5 Antagonist drugs 
Flumazenil, a benzodiazepine antagonist, and naloxone, an opioid antagonist, 
should not be routinely administered, but reserved for oversedation or severe 
respiratory depression. Close patient monitoring should continue following 
administration as symptoms may recur if the PSA drug is longer acting than its 
antagonist. (4, 32) 
 
2.5 Risks associated with sedation 
The SASA PSA guidelines (4) categorise and list the usual causes of sedation 
related adverse events: 
 “Factors related to drugs: 
o Drug interactions. 
o Drug overdose, including local anaesthetic toxicity. 
o Incorrect selection of drugs (e.g. opiates for painless procedures). 
o Prescription errors, particularly with oral formulations. 
o Drug combinations. 
o Unanticipated (pharmacogenetic) responses to drugs. 
o Unsupervised administration (e.g. by a parent at home). 
o Lack of knowledge of the pharmacokinetics and pharmacodynamics of 
drugs. 
 
 Factors related to skills: 
o Inadequate clinical evaluation, especially of the airway, and inappropriate 
patient selection. 
o Inadequate experience in paediatric sedation. 
o Inadequate problem recognition. 
o Inadequate support staff qualifications. 
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o Inability of the sedationist to rescue a patient from an unexpected or 
undesirable deep level of sedation. 
o Inadequate resuscitation skills. 
 
 Factors related to the environment: 
o Inadequate monitoring. 
o Inadequate equipment. 
 
 Premature discharge, and not following discharge criteria.” (4) 
 
The 1983 case reports, titled “Life-threatening reactions after pedodontic sedation: 
an assessment of narcotic, local anesthetic, and antiemetic drug interaction”, 
reviewed data from a combination of court records, case histories and published 
reports of 14 adverse outcomes following paediatric dental sedation, most of which 
resulted in death or neurological injury. Two of these cases will be described in an 
attempt to put into perspective the need at the time to put an end to such crises. (18) 
 
In the first case a four year old boy (15.4 kg) had breakfast at 07:00 on the day of the 
procedure and was given 50 mg promethazine orally at home 15 minutes thereafter. 
Promethazine is a sedating antihistamine with antiemetic effects. It is not 
documented who wrote the prescription or who was responsible for sedation. On 
arrival at the dental rooms at 08:10 the boy was “injected with” 16 mg alphaprodine 
(an opioid) and a further 1.25 mg promethazine. The route of administration of these 
drugs is not stated. Topical lignocaine (unknown dose) was then applied and 144 mg 
of the local anaesthetic prilocaine injected. At this stage the child had already 
received three times the maximum recommended dose of promethazine and more 
than one and a half times that of both alphaprodine and prilocaine. The boy 
appeared well sedated and was making light snoring sounds. A rubber dam was 
placed by the dentist and 20% inhaled N2O in oxygen initiated. No further details 
regarding the mode of administration of the N2O appear in the case report. Ten 
minutes later snoring stopped and the child became completely flaccid with 
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unrecordable vital signs. Inspection revealed vomitus in the airway. The only 
subsequent measures documented in the report were suctioning of the vomitus and 
administration of the opioid antagonist, naloxone. It is unclear whether the child 
became apnoeic, obstructed his airway, or aspirated gastric contents. The duration 
of hypoxia was not documented but the boy survived with permanent neurological 
injury as a result. (18) 
 
In the second case a three year old girl was given 25 mg meperidine (an opioid) and 
an unknown dose of hydroxyzine (a sedating antihistamine) as a pre-medication by 
her parents two hours prior to her procedure. It is not stated who wrote the 
prescription. On arrival at the dental rooms the dentist injected 30 mg alphaprodine 
(an opioid) subcutaneously into the buccal fold of the maxilla as the patient appeared 
to be in an excited state and her “condition suggested that the total amount of the 
oral medication was not completely ingested.” In addition to the unknown dose of 
hydroxyzine, the girl was given more than four times the maximum recommended 
dose of opioids. Her “respirations ceased” during the procedure and she was given 
sublingual adrenaline. The report does not mention any other resuscitative measures 
or the duration of apnoea. The girl recovered and the procedure was completed. She 
was discharged home following a two hour observation. Three hours later she was 
rushed back to the facility, with her father performing mouth-to-mouth resuscitation. 
The report does not discuss subsequent findings and treatment. The girl died several 
hours later. (18) 
 
The primary adverse event in all 14 cases was respiratory depression, brought about 
by high drug dosages and a lack of knowledge surrounding the additive effects of 
combining central nervous system depressants. None of the reports documented 
any monitoring of respiratory function. (18) 
 
There are no databases available to provide an estimate of the incidence of adverse 
events associated with paediatric dental procedures performed under sedation (35, 
36). Various studies have looked at adverse events during paediatric sedation in 
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general, but there have been no multicentre studies sufficiently large enough to 
estimate the incidence of relatively rare events of major morbidity and mortality as a 
result of dental chair sedation, either locally or internationally (2, 18, 26, 30, 33-38). 
In most studies describing sedation safety and adverse events, the patient cohorts 
contain tens or hundreds of patients and are statistically underpowered to report on 
the frequency of events that should occur in no more than one in many thousands (2, 
18, 26, 30, 34-37). These events do however occur and most of these occurrences 
are preventable. Since dental procedures are not perceived as potentially 
dangerous, the public does not accept the idea of a death in a dental chair (37). 
 
In 2006 the Paediatric Sedation Research Consortium, a group dedicated to 
improving sedation and anaesthesia care for children globally, reported on the 
incidence and nature of adverse events during paediatric sedation and anaesthesia 
outside the operating room. A total of 26 institutions submitted data on 30 037 
procedures. These included a variety of procedures of which only 1.1% were dental 
in nature. The information yielded, however, is important to all sedation performed 
outside the operating room. Serious events were rare, with no mortalities. One child 
required cardiopulmonary resuscitation and another aspirated gastric contents. 
Neither of these patients suffered any permanent injury. There was an overall 
complication rate of 5.3%. Oxygen desaturation, stridor, laryngospasm, unexpected 
apnoea, excessive secretions, and vomiting were among the complications. These 
adverse events were among those that occurred once in every 89 sedation 
encounters and which have the potential to do harm if timely rescue interventions are 
not instituted. Airway and ventilation interventions were required in 1 in 200 
sedations, which ranged from insertion of an oral airway to mask ventilation to 
emergency intubation. The authors conclude that serious adverse events are rare in 
facilities with highly motivated and organised sedation services, like those 
participating in their study, and that safety depends on the system’s ability to 
manage less serious events. (26) 
 
In an attempt to study rare events in an efficient way, a critical incident analysis was 
carried out on 118 adverse sedation events derived from reports received by the 
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Food and Drug Administration and the US Pharmacopeia, and a survey completed 
by paediatric specialists. Data were compared for hospital versus out-of-hospital 
facilities, with 33.7% of these cases being sedated by dental practitioners (mostly in 
an out-of-hospital setting). In both settings, respiratory compromise was the initially 
observed clinical event in more than 80% of patients. Subsequent cardiac arrest was 
three times more likely in out-of-hospital facilities. A final outcome of death or 
permanent neurological injury occurred more frequently in an out-of-hospital (92.8% 
of serious adverse events) versus hospital (37.2%) setting (p<0.001). These 
outcomes occurred despite children in an out-of-hospital setting being older and 
healthier. The most common contributory cause of these adverse sedation events 
was drug interactions (46.3% of cases). This occurred as a result of the additive 
effect of various PSA drugs on respiration. No particular drug or drug combination 
was singled out. Other common causes of adverse events included drug overdose 
(35.8%), inadequate monitoring (28.4%), inadequate resuscitation (20%), inadequate 
medical evaluation (18.9%), and premature discharge (11.6%). Inadequate 
resuscitation occurred more frequently (57.1% versus 2.3%) following out-of-hospital 
events. (2) 
 
The authors of the above study acknowledge that their database represents only a 
small subset of adverse sedation events, because most of the reported cases 
resulted in death or permanent neurological injury. The study, however, highlights 
the need for uniform guidelines for monitoring children during and after sedation. (2) 
The only help or backup available in an out-of-hospital setting may be that of the 
emergency medical services, whose arrival would take a long time in the face of a 
significant adverse event (20). Emergency drugs and equipment should therefore be 
immediately available regardless of the location (2). Most sedation complications can 
be managed with simple interventions such as providing oxygen, opening the airway, 
suctioning, and using mask ventilation. Hypotension and cardiopulmonary arrest that 
may occur usually arise from poor recognition and treatment of respiratory 
compromise. (20) All health care providers who sedate children should be skilled in 
airway assessment and management and be able to resuscitate children in the event 
of an adverse sedation event occurring (2). 
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In another American study, adverse events and outcomes related to procedural 
sedation by non-anaesthesiologists were examined in order to identify patient factors 
and anaesthetic techniques that would predict an increased risk of sedation mishaps. 
Of the 1140 children sedated, 20.1% experienced at least one adverse event, whilst 
150 (13.2%) children were inadequately sedated, which led to 43 failed procedures. 
(34) Inadequate sedation may lead to patient discomfort or injury because of a lack 
of cooperation or an adverse physiological or psychological response to stress (21). 
A respiratory event (respiratory depression, upper airway obstruction, or apnoea) 
leading to oxygen desaturation was experienced by 5.5% of children. Three of these 
children did not desaturate until after the procedure, with one having been awake 
throughout and then became sedated and subsequently desaturated in the recovery 
area. The cause of desaturation is not documented in the report. Other adverse 
events included hypotension, bradycardia, vomiting, paradoxical reactions involving 
agitation and excitation, and one case of supraventricular tachycardia. All adverse 
events were managed and no long-term sequelae transpired. An increased 
incidence of adverse events occurred in infants and ASA 3 or 4 patients (compared 
with ASA 1 or 2; p < 0.0001). (34) Amongst other findings, the importance of patient 
selection and appropriate recovery area monitoring arise out of this study, which are 
both emphasised in the SASA PSA guidelines (4, 34). 
 
Due to the lack of systematic data collection on outcomes of paediatric dentistry, Lee 
et al. (36) analysed American media reports of children who died subsequent to 
receiving sedation or general anaesthesia for dental procedures between 1980 and 
2011. Of the 44 reports analysed, most deaths occurred in children under six years 
of age (52.3%), in an office setting (70.5%), and with a dentist as the sedation or 
anaesthesia provider (56.8%). The authors indicate that due to a lack of systematic 
reporting, these deaths represent only a subset of a larger number of deaths. (36) 
 
Children may pass into a deeper state of sedation than intended. A study of 960 
children being sedated by non-anaesthesiologists for various procedures found that 
18% of the 895 patients who required conscious (mild to moderate) sedation had 
inadvertently slipped into a state of deep sedation. In this study there was a 3.8% 
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rate of complications with planned conscious sedation compared to 9.2% with 
planned deep sedation (OR: 2.6). Sustained hypoxaemia, airway obstruction, 
apnoea, aspiration, hypotension, and prolonged sedation accounted for the 
excessive risk associated with deep sedation. (3) One cannot be certain what dose 
of a sedative will cause deep sedation in a child (39). Noxious stimuli may lighten 
sedation, while withdrawing stimuli at the end of a procedure can deepen it (32). A 
sedationist may be tempted to use larger doses of drugs in an uncooperative child. 
Sedatives that are said to have a wide margin of safety are generally not short acting 
and, should deep sedation occur, it may be prolonged. (39) It is therefore essential to 
have knowledge of the different levels of sedation (28), which should only be 
undertaken where facilities, equipment and personnel are always prepared and 
equipped to manage deep sedation (39). 
 
Despite the risks associated with PSA, it is neither realistic nor necessary to restrict 
its provision to anaesthesiologists, who are insufficient in number to cater for the 
ever increasing need for paediatric PSA (31, 40, 41). 
 
2.6 2010 SASA PSA guidelines 
The ASA (21) states that: “Practice guidelines are systematically developed 
recommendations that assist the practitioner and patient in making decisions about 
health care. These recommendations may be adopted, modified, or rejected 
according to clinical needs and constraints. Practice guidelines are not intended as 
standards or absolute requirements. The use of practice guidelines cannot 
guarantee any specific outcome. Practice guidelines are subject to revision as 
warranted by the evolution of medical knowledge, technology, and practice.” 
 
As dental chair sedation practices in Gauteng will be compared to the standards 
described by the 2010 SASA PSA guidelines (4), the relevant contents of these 
guidelines will be discussed in detail. 
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These guidelines were developed by a task team at the request of the Department of 
Health of the Western Cape. The team felt that the guidelines would be of benefit to 
the entire country and in line with the international trend towards the formalisation of 
sedation guidelines for children. It is based on international and national peer-
reviewed publications and numerous other medical disciplines were consulted in the 
process. The emphasis of the document is on the provision of safe practice and a 
unified standard of care, regardless of location. The document is the first of its kind in 
this country and its information is relevant to South African practice. (4) 
 
Outline of the content of the guidelines, with particular reference to this study are 
discussed in more detail below: 
2.6.1 Introduction, objectives, definitions 
The guidelines are intended for use by dental and medical practitioners across all 
disciplines providing sedation, analgesia and anxiolysis to paediatric patients 
undergoing diagnostic or therapeutic procedures. Safety should be ensured in all 
environments. (4) 
 
The relevant definitions are those provided in the “Research assumptions” section of 
this report. The response of individual patients to drugs administered is difficult to 
predict, and practitioners must be able to rescue patients who inadvertently enter a 
deeper level of sedation than intended. The document states that deep sedation and 
general anaesthesia should only be performed by those with anaesthetic training, but 
does not specify what level of anaesthetic training is required. (4) 
 
2.6.2 Patient selection 
Children at increased risk for complications should at least be assessed by a 
specialist anaesthesiologist (or experienced sedation practitioner). This person does 
not need to be the sedationist but should be available for consultation and, 
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preferably, assistance. Such cases should preferably be sedated in a hospital setting 
and not in a dental practice. These patients include: 
 “Age < 1 year.  Prematurity with residual pulmonary, cardiovascular, gastrointestinal or 
neurological problems, or significant anaemia.  Children with congenital syndromes.  Obesity (> 95th percentile body mass index (BMI) for age).  Children who need an advanced sedation technique.  A previous failed sedation.  A previous oversedation (unintentional deep sedation or general anaesthesia).  Any known adverse effect (hyperactive or paradoxical response) or allergy to 
any of the sedation drugs.  Any child who, following airway assessment…, is suspected of having airway 
problems.  Children with respiratory problems, including an active URTI, low oxygen 
saturation, and a weak cough or cry.  Asthmatic children who are clinically wheezing or whose regular treatment 
includes more than inhalational short-acting ß2–agonists and inhalational 
steroids.  Children with cardiac problems, including congenital cardiac disease, cyanosis, 
congestive heart failure and undiagnosed murmurs.  Neurological conditions, including poorly-controlled seizures, neuromuscular 
disease, central apnoea or an unstable cervical spine.  Increased intracranial pressure.  Severe behavioural problems.  Uncontrolled gastro-oesophageal reflux or other conditions predisposing to 
reflux.  Active vomiting.  Haematological conditions, including coagulation disorders and sickle cell 
disease.  ASA class 3 and 4.  Parental reluctance. 
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 Children with malignancies.” (4) 
 
A few of the listed subgroups will be elaborated upon. A study by Malviya et al. (34) 
(discussed in more detail earlier in this report) looking at adverse paediatric sedation 
events found an increased incidence of adverse events among infants and ASA 3 
and 4 patients. The risk of anaesthesia-related cardiac arrest is inversely 
proportional to age, with the highest incidence occurring among infants (42). An 
analysis of anaesthesia-related cardiac arrests from the American Pediatric 
Perioperative Cardiac Arrest Registry found that more than a third of paediatric 
cardiac arrests occurred in infants, while 75% of arrests occurred in ASA 3 to 5 
children (43). 
 
Congenital syndromes usually involve more than one body system. Depending on 
the particular syndrome, factors that may impact on patient safety may include a 
difficult airway (upper or lower airway obstruction or defects), impaired respiratory 
mechanisms (caused by skeletal abnormalities or altered respiratory drive), gastro-
oesophageal reflux, cardiovascular disorders (structural defects or arrhythmias), 
neuromuscular problems, liver or kidney disease (with impaired drug clearance). (44) 
 
With regards to obesity potential problems involve, amongst others, airway 
management (increased risk of airway obstruction with difficulty ventilating and or 
intubating patients should the need arise), a predisposition to hypoxia, and 
obstructive sleep apnoea with possible pulmonary hypertension (45). An American 
closed-claim analysis found obesity to be a significant risk factor for major morbidity 
or mortality from dental office anaesthetic procedures (37). 
 
The incidence of laryngospasm during anaesthesia in children under nine years of 
age is 1.74%. Although this reference is made to anaesthesia and not sedation, it is 
during the period of induction and emergence, rather than during deep general 
anaesthesia, when patients are most vulnerable. Laryngospasm causes airway 
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obstruction and hypoxia, and if unresolved may eventually result in cardiac arrest. 
Children with an upper respiratory tract infection or active asthma have irritable 
airways and are approximately ten times more prone to developing laryngospasm. 
(27) 
 
There are other children whom the sedationist should treat cautiously and have a low 
threshold for referring to a higher level of care. These children include those younger 
than five years old, children with a head injury, epilepsy, autism, an altered mental 
state, communication problems, delayed milestones, controlled gastro-oesophageal 
reflux, and children taking psychotropic medication. (4) 
 
2.6.3 Patient assessment 
Guidelines to a comprehensive history, airway and physical examination are 
provided. This facilitates identification of patients at increased risk (mentioned 
above), who would warrant additional consultation or referral. Informed consent 
should be obtained from a responsible person. (4) 
 
2.6.4 Fasting guidelines 
Information is given on standard fasting guidelines. Fasting is not required for simple 
sedation techniques. (4) 
 
2.6.5 Drugs 
A summary of the drugs used during PSA and their antagonists appear in this 
section. Practitioners are reminded of the synergistic effects of using drugs in 
combination and to allow a drug-specific period to elapse before administering 
repeated doses of a drug. Recommendations are made as to which drugs are not 
suitable for outpatient procedures and which agents should be used only by 
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practitioners with anaesthetic training. (4) This part of the guidelines is discussed in 
more detail in the “Pharmacology” section of this report. 
 
2.6.6 Environment 
Sedation should only be performed in an environment capable of handling 
emergencies. A comprehensive list is provided of the minimum equipment that must 
be available and regularly checked. These include equipment to: 
 open and protect the airway (a range of sizes)  confirm endotracheal intubation (including stethoscope and end-tidal carbon 
dioxide monitoring)  assist with difficult intubation  deliver oxygen and ventilation  diagnose and treat dysrhythmias  gain intravascular access  infuse fluids  monitor airway, breathing and circulation. (4) 
 
2.6.7 Monitoring 
 Clinical monitoring: 
This includes observation of chest wall and face, assessment of level of 
consciousness, colour, respiratory rate and pattern, and signs of pain or anxiety. The 
document contains a description of the above variables. (4) 
 
 Equipment: 
During simple or basic sedation pulse oximetry is necessary. During advanced 
sedation pulse oximetry, ECG and non-invasive blood pressure monitoring is 
necessary and capnography (or a praecordial stethoscope) recommended. (4) 
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 Personnel: 
During simple or basic sedation the patient must be monitored by someone other 
than the operator. As advanced sedation is more complicated closer monitoring is 
required. Someone other than the operator must administer sedation, monitor the 
patient, and be responsible for rescuing the patient should complications arise. A 
medical practitioner is recommended to perform this role. (4) 
 
2.6.8 Discharge 
Premature discharge has been identified as a major cause of severe morbidity and 
mortality.  A scoring system for discharge readiness from the recovery area to the 
ward (in the case of inpatient sedation) is provided as a guide. It assesses level of 
consciousness, respiration, oxygen saturation, movement, temperature and pain. 
Additional criteria need to be met should children be discharged home. These 
include the absence of surgical complications, ability to drink fluids, no nausea or 
vomiting and an analgesia management plan. A simple questionnaire to aid in this 
process is provided. (4) 
 
Children may be only discharged from the facility into the care of a parent, guardian, 
or another responsible person. This person must have access to a telephone and be 
given clear instructions which should include: 
 not leaving the child unattended in a car   slow initiation of eating and drinking  avoiding play requiring coordination for 12 hours  supervising all activity for 12 hours   where to seek immediate help or a telephone number to phone   how to give prescribed medication. (4) 
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2.6.9 Documentation required 
“It is important to remember that, unless it has been written down, it never 
happened!” (4) 
 
Documentation is necessary before, during and after sedation. This includes:  
 a medical history questionnaire  informed consent  pre- and post-sedation instructions to the caregiver  a pre-procedural checklist (including an equipment check)  a sedation monitoring chart  a post-sedation monitoring chart, with a discharge scoring system  a discharge questionnaire. 
Each of these documents is explained in more detail in the guidelines, with 
accompanying templates and suggested formats. (4) 
 
2.6.10 Adverse events 
The causes of adverse events are as listed and discussed in the “Risks associated 
with sedation” section of this report. Audits of procedures as well as critical events 
should be performed at least annually. A suggested adverse event reporting form is     
provided in the guidelines. (4) 
 
2.6.11 Procedure specific recommendations 
Pharmacological and non-pharmacological strategies are suggested. The latter 
includes psychological preparation of the child and caregiver, distraction, application 
of ice packs etc. PSA recommendations are made for various diagnostic and 
therapeutic procedures, of which only dental PSA will be discussed here. (4) 
 
34 
 
Recommended PSA techniques include: 
 using topical and local anaesthesia for analgesia;  a basic technique using not more than 50% inhaled N2O in oxygen is one of the 
best techniques for minor paediatric dental procedures;  oral drugs (e.g. midazolam) can be used (but must be administered on the 
premises and not at home);  advanced techniques may be useful. (4) 
 
Anaesthetic doses of drugs (i.e. doses large enough to induce general anaesthesia) 
should not be used and doses should be reduced if a combination of sedative agents 
is administered. The timing of administration of PSA drugs in relation to stimulation 
of a patient is important and will prevent excessive doses being given. This highlights 
the importance of the pharmacology section of the guidelines, which describes the 
time of onset and duration of action of the recommended PSA drugs. (4) 
 
2.6.12 Setting up a sedation service 
Aspects that deserve attention, irrespective of techniques employed are: 
 environment, patient selection and assessment: 
Patient selection and assessment, including a focused airway examination, must be 
done by trained healthcare professionals and documented. All facilities must comply 
with standards for patient safety. (4) 
 
 training requirements: 
All sedation practitioners must comply with SASA recommendations and 
contemporary standards of training. If administering moderate or deep sedation, 
Pediatric Advanced Life Support (PALS) or Advanced Pediatric Life Support (APLS) 
certification is highly recommended. (4) 
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 sedation practitioner: experience and ability to rescue: 
Continuing professional development is important. Practitioners must be able to 
rescue patients who progress to an inadvertent deeper level of sedation. (4) 
 
 record keeping: 
A register of procedures performed and sedation techniques used must be kept (4). 
 
2.7 Society of Sedation Practitioners of South Africa (SOSPOSA) 
Being a useful source of support to sedation practitioners and the only sedation 
society in South Africa affiliated to SASA, it is worth making a short mention about 
SOSPOSA. It is a member of the International Federation of Dental Anesthesiology 
Societies and a special interest group of SASA, which brings together practitioners 
from various disciplines who are involved and interested in sedation practice. 
Amongst other benefits, members have access to the latest information regarding 
safe sedation practice, are able to ask questions on sedation-related issues, and 
receive information regarding training opportunities. SOSPOSA endorses the SASA 
PSA guidelines (4) and promotes application of the guidelines to its members as an 
important step in ensuring safe sedation practice. (46) 
 
2.8 Dental sedation survey 
Goodchild et al. (47) conducted a study examining the use of outpatient dental 
sedation in the United States and Canada in May 2009. Their study is discussed 
here as it shares many similarities with this one in terms of design and information 
sought. An email was sent to 7246 dentists requesting participation in a short web-
based survey. Responses were voluntary and kept anonymous. Participants were 
asked about their use of sedation, type of sedation used, drugs and their 
antagonists, route of administration, monitoring employed and availability of a 
defibrillator. There was a 9.84% response rate. The authors attribute the low 
response rate to email filters, participants not being acquainted with the authors and 
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that emails were sent from one of the author’s personal email accounts. Of the 716 
completed surveys, 76% of practitioners used sedation with 26% of the remaining 
dentists being interested in doing so. Nitrous oxide and oxygen was the most 
common type of sedation employed (77% of practices). Inhalation was the most 
common route of administration (75%) and parenteral sedation the least common. 
Blood pressure was monitored in 84% of patients and pulse oximetry in 81%, while 
5% of respondents did not use any monitoring equipment. Benzodiazepines were the 
most frequently used drugs for enteral sedation (90%), although only 75% of 
respondents carried antagonist drugs. A defibrillator was available in 64% of 
facilities. (47) 
 
2.9 The benefit of applying guidelines to sedation practice 
Various professional bodies (e.g. ASA, AAP) have published guidelines in attempts 
to enhance the safety of PSA by the application of standards. Since these standards 
are based largely on expert opinion, differ from each other, and restrict practice, they 
have not been uniformly accepted and applied. (3) 
 
No study could be identified that determined risk reduction from the application of the 
SASA PSA guidelines (4) per se. The content and safety recommendations 
contained in these guidelines are, however, similar in nature to those developed by 
other bodies. A co-author of the critical incident analysis (2) discussed earlier stated 
in another publication (31) that, since outcomes of death and permanent neurological 
events were quite uncommon, a much larger sample size (several hundred thousand 
or more) would be needed to demonstrate the efficacy of sedation guidelines in 
preventing such outcomes. 
 
Cote (31) states that: “If you ask me how to measure the cost/benefit ratio of 
implementing the sedation guidelines, I say we cannot measure it. We can, however, 
say there is a heightened awareness of the problems associated with sedation, there 
is better evaluation of patients before sedation, there is more attention to developing 
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institutional guidelines... and I am sure some lives have been saved; we just can’t 
measure this outcome.” (31) 
 
A study conducted at the Children’s Hospital of Wisconsin found direct evidence that 
elements of the AAP/ASA guidelines for procedural sedation could be adopted by 
non-anaesthesiologists with a decrease in the occurrence of complications or 
adverse events. A quantitative scoring system assessed adherence to essential 
components of the guidelines during the sedation of 960 children for a variety of 
procedures. Analysis of the data revealed significant variation in practice. 
Performance of a structured patient risk assessment (OR: 0.10) and adherence to all 
process guidelines (OR: 0) significantly reduced complications. Although the study 
does not determine which specific elements of the risk assessment were associated 
with risk, it does indicate that a guided assessment is important in identifying patients 
at risk for sedation complications. Repeated assessment of the depth of sedation, as 
recommended by the guidelines, also reduces the risk of inadvertent deep sedation. 
(3) 
 
Vade et al. (30) demonstrated the importance of applying guidelines in their entirety. 
The aim of their study was to compare the frequency of adverse events associated 
with different drug regimens during paediatric sedation for radiological studies. They 
selected 410 children, and monitored and managed them according to the AAP 
sedation guidelines at that time. Two patients suffered moderate to severe hypoxic 
events during sedation, which were appropriately managed. Errors were made 
during pre-sedation medical screening, as these children had significant co-
morbidities and according to the guidelines were inappropriately selected to undergo 
sedation. Two important points that arose from this situation are relevant to this 
review. Firstly, it highlights the importance of appropriate patient selection and 
evaluation in preventing adverse events and secondly, as the authors conclude, 
adoption of the guidelines allowed for prompt detection and management of 
potentially life-threatening hypoxia. (30) 
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Guidelines cannot guarantee a specific patient outcome, but encourage high quality 
patient care (6). Exactly when a problem will develop can’t be predicted with 
certainty, so if all patients are monitored equally it is less likely that an impending 
adverse outcome will be missed. 
“Minor desaturation is much easier to correct than a hypoxic-induced cardiac arrest!” 
(31) Sedation practitioners must try to avoid adverse outcomes, and have the ability 
and equipment to rapidly diagnose and adequately manage them should they occur. 
 
2.10 Summary 
Dental chair PSA facilitates the successful completion of procedures in children, who 
would otherwise not be able to receive treatment or would require a costly general 
anaesthetic in a hospital setting. PSA is generally safe and although serious adverse 
events are rare, those that occur are mostly preventable. Children comprise a 
particularly vulnerable patient subgroup.  
 
Cases of major morbidity and mortality during sedation for harmless dental 
procedures in healthy children were reported in the United States during the 1980’s. 
This prompted authorities to develop sedation guidelines, which were shown to 
improve safety and reduce adverse outcomes associated with PSA.  
 
In South Africa, SASA published the country’s first PSA guidelines in 2010 (4), which 
provide a framework for the provision of safe sedation and analgesia for diagnostic 
and therapeutic procedures in children. However, little is known about the extent of 
adverse dental chair PSA outcomes in South Africa, the awareness of the SASA 
PSA guidelines (4), or the state of safety standards for PSA in dental rooms. 
 
This chapter comprised a review of the current relevant literature. In the next chapter 
the research methodology and study considerations are covered in detail. 
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CHAPTER THREE 
RESEARCH DESIGN AND METHODOLOGY 
 
3.1 Introduction 
In this chapter the following will be discussed: the problem statement, aim and 
objectives of the study; ethical considerations; research methodology; and the 
validity and reliability of the study. 
 
3.2 Problem statement 
PSA is generally safe, and is often necessary to successfully undertake dental 
procedures in children. Severe adverse events and outcomes that occur are mostly 
preventable. The guidelines formulated by SASA serve to provide a framework for 
practitioners to safely provide PSA to children in all environments (4). 
 
No data could be identified as to how many dental practices in Gauteng make use of 
PSA and how many sedation practitioners are aware of the available SASA PSA 
guidelines (4). Practising outside the framework of these guidelines may place 
children at increased risk of adverse events and outcomes. 
 
3.3.1 Aim 
The aim of this study was to determine the proportion of dental practitioners making 
use of paediatric dental chair PSA in Gauteng and to describe paediatric dental chair 
PSA practice, awareness of the 2010 SASA PSA guidelines (4), and adherence to 
the guidelines. 
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3.3.2 Objectives 
The objectives of this study were to: 
 determine the proportion of dental practitioners in Gauteng that utilise paediatric 
dental chair PSA;  identify the professional category of person primarily responsible for 
administering PSA;  describe the modalities of PSA administered in dental rooms  
o depth of sedation 
o drugs used 
o number of sedative agents used in combination 
o routes of administration;  describe the sedation and resuscitation training of PSA providers;  determine adherence to recommended safety standards for prevention of 
adverse events 
o age groups of children sedated 
o ASA physical status 
o pre-sedation assessment and informed consent 
o fasting 
o person responsible for patient monitoring 
o monitoring equipment 
o level of consciousness or depth of sedation monitoring 
o recovery;  determine adherence to recommended safety standards for management of 
adverse events 
o emergency drugs 
o emergency equipment;  determine the occurrence of complications of PSA. 
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3.4 Ethical considerations 
Approval to conduct this study was obtained from the Postgraduate Committee 
(Appendix 1) and the HREC (Medical) (Appendix 2) of the University of the 
Witwatersrand. 
 
A sample of Gauteng-based members of SADA, whose names and contact numbers 
are available to the public on the SADA website (8), were invited telephonically by 
the researcher to participate in the study. Dental practitioners who agreed to 
participate, and who indicated that paediatric PSA was being performed in their 
rooms, were then sent an introductory email detailing the purpose of the study, 
content of the data collection email, rights to anonymity and withdrawal, and ethics 
approval (Appendix 4). Consent to participate was implied when the participant 
clicked on a link contained in the email to a web-based data collection sheet 
(Appendix 3) developed using the online survey site, SurveyMonkey™. 
Confidentiality and anonymity of information were ensured as all responses were 
uploaded anonymously onto an electronic database on the SurveyMonkey™ 
website. It was not possible to trace information back to individual participants and 
the researcher and supervisors were the only people with access to this database by 
way of a unique user name and password. 
 
A CPD-accredited sedation seminar hosted by the Department of Anaesthesiology, 
Charlotte Maxeke Johannesburg Academic Hospital was offered to participants to be 
held upon completion of this study, as it would be unethical to continue providing 
PSA without awareness of recommended safety standards. 
 
This study did not involve any drug or therapeutic management and no patient was 
directly involved. It was conducted in accordance with the Declaration of Helsinki 
(10) and the South African Good Clinical Practice Guidelines (11). 
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3.5 Research methodology 
3.5.1 Study design 
A prospective, contextual, descriptive survey study design was used. 
 
A prospective study is defined as a study which measures variables that occur 
during the course of the study and not those that have occurred in the past (48). In 
this study, variables pertaining to paediatric dental chair sedation practice were 
measured at the time in which the study took place. 
 
A contextual study is conducted in a specific location (48). This study was carried out 
in Gauteng only. 
 
A descriptive study is used when more information is required in a particular field and 
describes the variables in order to answer the research question, with no intention of 
establishing a cause-effect relationship. The emphasis in the collection of data is on 
structured observation, questionnaires, interviews or survey studies. (48) This study 
was descriptive in nature as it aimed to gain information about paediatric dental chair 
sedation practice. 
 
3.5.2 Study population 
Qualified dental practitioners who were listed on the SADA website and practising in 
Gauteng formed the population group studied (8). 
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3.5.3 Study sample 
3.5.3.1 Sample size 
The names and contact numbers of 1152 Gauteng-based SADA members were 
listed on the SADA website (8). Two hundred dental practitioners were invited to 
participate in the study. As it was not known what proportion of dentists utilise 
paediatric PSA, this figure (n=200) would be increased following initial data collection 
if necessary, until a minimum of 20 completed data collection sheets were received 
(i.e. until at least 20 of the practitioners contacted were found to utilise PSA in their 
rooms and completed the data collection sheet). The sample size was influenced by 
available resources (financial and time constraints) and the scope of the study. 
 
3.5.3.2 Sampling method 
A simple random sampling method was used in this study. Simple random sampling 
involves a one-stage selection process in which each participant is listed separately 
and has an equal chance of being drawn (48). The sampling frame comprised the list 
of 1152 Gauteng-based SADA members whose details are available to the public on 
the SADA website (8). SADA is the most recognised and representative body of 
dentists in South Africa (9). Furthermore, a randomly selected number from one to 
one million was allocated to each of the 1152 members using the website 
Random.org (49). The reason for using one million possible numbers, despite a 
sampling frame of only 1152 members, was to avoid allocating the same number to 
more than one member. The randomly allocated numbers were then arranged from 
smallest to largest, with the first 200 numbers (and corresponding SADA member on 
the list) comprising the study sample (Appendix 5). The same technique would be 
employed to select more participants from the remainder of the sampling frame 
should the need for a larger sample be identified following initial data collection. 
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3.5.3.3 Inclusion and exclusion criteria 
All Gauteng-based dental practitioners who were members of SADA and listed on 
the SADA website on 23 June 2012 were included in the study (8). Members who 
declined to participate were excluded. 
 
3.5.4 Data collection 
A web-based data collection sheet (Appendix 3) was designed for data collection 
using SurveyMonkey™.  
 
Prior to developing the data collection sheet, a review of the literature was done in 
order to identify the potential safety pitfalls in the field of paediatric dental chair PSA. 
The SASA PSA guidelines (4) highlight the standards required to safely administer 
PSA to children. These guidelines were reviewed in depth and served as the main 
reference point for the development of the data collection sheet, which for the most 
part assessed adherence to safety standards by comparing participants’ PSA 
practice with the recommendations set out by the guidelines. Previous studies in 
which similar information was sought were used as additional guides in developing 
the data collection sheet (3, 47).  
 
The data collection sheet was designed to be short and concise in an attempt to 
ensure a good response from participants. It assessed items in the following 
categories: 
 professional category of person responsible for administering PSA  modalities of sedation used  awareness of the SASA PSA guidelines  sedation and resuscitation training of the sedationist  patient selection and assessment  monitoring  recovery area and discharge 
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 emergency drugs and equipment  complications. 
 
The data collection sheet was developed in consultation with three 
anaesthesiologists in order to ensure accuracy and validity. Two of these experts in 
the field are consultants in the Department of Anaesthesiology at the University of 
the Witwatersrand, with a special interest in paediatric anaesthesia. The third expert 
is part of a private-sector specialised sedation practice based in Johannesburg.  
 
Once approval was obtained from the HREC (Medical), the dental practitioners 
randomly selected from the sampling frame were invited to participate in the study by 
means of a structured telephone conversation. Those practitioners who agreed to 
participate and who utilised PSA in children in their dental rooms were sent an email 
comprising an introductory letter (Appendix 4) and a link to the web-based data 
collection sheet (Appendix 3). The email address was set up specifically for the 
purpose of the study and did not contain the name of the researcher. Data received 
from completed data collection sheets was uploaded anonymously onto a database 
on the SurveyMonkey™ website, where it was analysed. Since all responses were 
received in an anonymous manner, it was not possible to ascertain which individuals 
did not respond. A reminder was emailed to all members two weeks after the initial 
email to thank those practitioners who had completed the data collection sheet and 
to serve as a reminder to those who had not yet done so (Appendix 6). The data 
collection process is illustrated in Figure 3.1. 
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Figure 3.1 Data collection process 
PSA = procedural sedation and analgesia 
*There was no way to ascertain who had not responded to the initial email as responses were anonymous. 
 
3.5.5 Data analysis 
Incoming data was analysed as it was received by SurveyMonkey™, the website 
hosting the data collection sheet. Descriptive statistics using frequencies and 
percentages were used to analyse the data. A proportion and confidence interval 
were determined with support from a biostatistician. 
 
3.6 Validity and reliability 
Validity and reliability of the study and data collection sheet were ensured by the 
following. 
 A representative sampling frame. SADA members form a good representation of 
dental practitioners in South Africa.  Randomisation of the sampling frame to minimise sampling bias. 
 
 
Dental practitioners phoned. 
Agreed to participate? 
 
 
 
NO 
Excluded 
 
YES 
Utilised PSA in children? 
 
 
 
YES 
Link to data collection sheet 
emailed 
 
NO 
 
 
*Reminder email sent to 
responders and non-
responders 2 weeks later 
  
 
 
Data capture and analysis 
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 Content validity. The data collection sheet was designed following a careful 
review of the literature. It was developed in consultation with three experts in the 
field, all of them specialist anaesthesiologists. Two of these experts are 
consultants in the Department of Anaesthesiology at the University of the 
Witwatersrand, with a special interest in paediatric anaesthesia. The third expert 
is part of a private-sector specialised sedation practice based in Johannesburg.  Criterion-related validity. Instruments used and variables assessed in similar 
studies were used as a guide in the development of the data collection sheet.  A short and concise data collection sheet. This minimised the test effect of 
fatigue that occurs with lengthy surveys (48).  An anonymous web-based data collection sheet. 
 
3.7 Summary 
In this chapter the following was addressed: the problem statement, aim and 
objectives of the study; ethical considerations; research methodology; and the 
validity and reliability of the study. The next chapter presents the results of this study 
and a discussion of the results. 
  
48 
 
CHAPTER FOUR 
RESULTS AND DISCUSSION 
 
4.1 Introduction 
In this chapter the results of this study are presented as per the research objectives. 
The data presented include: 
 the proportion of dental practitioners in Gauteng that utilise paediatric dental 
chair PSA;  the professional category of person primarily responsible for administering PSA;  the modalities of PSA administered in dental rooms 
o depth of sedation 
o drugs used 
o number of sedative agents used in combination 
o routes of administration;  sedation and resuscitation training of PSA providers;  adherence to recommended safety standards for prevention of adverse events 
o age groups of children sedated 
o ASA physical status 
o pre-sedation assessment and informed consent 
o fasting 
o person responsible for patient monitoring 
o monitoring equipment 
o level of consciousness or depth of sedation monitoring 
o recovery;  adherence to recommended safety standards for management of adverse 
events 
o emergency drugs 
o emergency equipment;  occurrence of complications. 
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4.2 Results 
The sum of percentages presented in this section may not add up to 100% due to 
rounding off to two decimal places. 
 
4.2.1 Sample realisation 
During the two month data collection period (April 2013 to May 2013), 222 dental 
practitioners were contacted telephonically. Nine practitioners were excluded from 
the study as they are not in clinical practice or have retired. Thirteen practitioners 
returned phone calls after the first 200 practitioners had already been interviewed 
and were included in the study. The data analysis thus included 213 dental 
practitioners, which comprised 195 general dentists and 18 specialists (6 
orthodontists, 5 periodontists, 4 maxillofacial surgeons and 3 prosthodontists). 
 
Ninety-four of the 213 dental practitioners interviewed use paediatric dental chair 
PSA. The participant information letter (Appendix 4) and reminder email (Appendix 
6) containing a link to the data collection sheet (Appendix 3) were sent to 93 of the 
94 practitioners. One respondent indicated that he did not have an email address 
and was therefore not sent a data collection sheet.  
 
Of the 93 data collection sheets issued, 52 (55.91%) were returned and uploaded 
onto the SurveyMonkey™ database for further analysis. Dental practitioners were 
not obliged to respond to each question in the data collection sheet. Respondents 
who did not answer individual questions were excluded from the analysis of data 
collected from those questions. 
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4.2.2 Demographics 
Forty-four dental practitioners indicated their age and gender on the data collection 
sheet. The mean age of respondents was 44.91 years old (range 24 - 74 years old), 
with 29 (65.91%) males and 15 (34.09%) females. 
 
Fifty dental practitioners indicated the frequency of PSA procedures performed. This 
data is presented in Table 4.1. 
 
Table 4.1 Frequency of PSA procedures performed 
Procedures per month Dental practitioners 
n % 
1-5 37 74 
6-15 10 20 
16-30 2 4 
31-50 1 2 
More than 50 0 0 
Total 50 100 
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4.2.3 Objective 1: The proportion of dental practitioners in Gauteng that utilise 
paediatric dental chair PSA 
Of the 213 dental practitioners interviewed, 94 (44.13%; 95% CI, 0.37-0.51) use 
paediatric dental chair PSA. Table 4.2 presents this data, which is broken down 
according to the dental subspecialists that were interviewed. 
 
Table 4.2 Proportion of practitioners using paediatric dental chair PSA in Gauteng 
Subspecialty 
Dental chair PSA 
Total interviewed YES 
n (%) 
NO 
n (%) 
General dentists 91 (46.67) 
104 
(53.33) 195 
Max-facs* 1 (25.00) 
3 
(75.00) 4 
Prosthodontists 0 (0.00) 
3 
(100.00) 3 
Periodontists 2 (40.00) 
3 
(60.00) 5 
Orthodontists 0 (0.00) 
6 
(100.00) 6 
Total 94 (44.13) 
119 
(55.87) 213 
*Max-facs = maxillofacial surgeons
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4.2.4 Objective 2: Professional category of person primarily responsible for 
administering PSA 
Forty-eight respondents indicated the professional category of person primarily 
responsible for administering PSA in their dental rooms. Table 4.3 presents this data. 
 
Table 4.3 Professional category of person primarily responsible for administering 
PSA 
Responsible person Dental practices 
n % 
Dental practitioner* 22 45.83 
Qualified nurse 0 0.00 
Medical practitioner 1 2.08 
Medical practitioner with 
sedation training 15 31.25 
Anaesthetist 10 20.83 
Total 48 99.99 
*The practitioner performing the dental procedure
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4.2.5 Objective 3: The modalities of paediatric sedation administered in dental 
rooms 
  Depth of sedation 
Forty-eight dental practitioners indicated how deeply patients are sedated in their 
rooms. Respondents could select more than one depth of sedation if applicable to 
their practice. Twenty-seven (56.25%) practitioners perform procedures under 
minimal sedation and 25 (52.08%) utilise moderate sedation. Deep sedation (5 
practices; 10.42%) and general anaesthesia (1 practice; 2.08%) are provided in 
fewer dental rooms. These results are broken down into professional categories of 
PSA providers and illustrated in Figure 4.1. 
 
Figure 4.1 Depth of sedation used for dental chair PSA and the professional 
category of PSA providers 
 
*Professional category of person primarily responsible for administering PSA 
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 Drugs used for PSA 
Forty-eight dental practitioners indicated the drugs used for PSA in their rooms. Two 
of these practitioners indicated that they were not sure what agents are used by the 
PSA provider. Table 4.4 presents the drugs used for PSA and the professional 
category of person primarily responsible for administering the drugs. Respondents 
could select more than one drug if applicable to their practice.
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Table 4.4 Drugs used for PSA and the professional category of PSA providers 
Name of drug 
Dental 
practices 
n (%) 
Primary PSA provider 
D
ental 
p
ractition
er
 
A
n
aesth
etist
 
M
edic
al 
p
ractition
er
 
w
ith
 sed
atio
n
 
training
 
M
edic
al 
p
ractition
er
 
N
ot
 indicated
 
Midazolam 33 (68.75) 10 7 13 1 2 
Local anaesthetic 
agents 
28 
(58.33) 12 5 10 0 1 
Nitrous oxide 19 (39.58) 13 2 3 0 1 
Propofol 13 (27.08) 1 2 9 0 1 
Ketamine 12 (25.00) 1 1 9 0 1 
Myprodol™ 12 (25.00) 6 3 3 0 0 
Diazepam 10 (20.83) 4 2 3 0 1 
Stopayne™ 9 (18.75) 4 1 3 0 1 
Paracetamol 9 (18.75) 4 2 3 0 0 
NSAIDs* 8 (16.67) 4 1 3 0 0 
Alfentanil 5 (10.42) 1 1 3 0 0 
Trimeprazine 4 (8.33) 1 1 1 0 1 
Fentanyl 2 (4.17) 0 1 1 0 0 
Dexmedetomidine 1 (2.08) 0 0 0 0 1 
Meperidine 1 (2.08) 0 1 0 0 0 
Lorazepam 1 (2.08) 1 0 0 0 0 
Tilidine 1 (2.08) 0 0 0 0 1 
Clonidine 0 (0.00) 0 0 0 0 0 
Chloral hydrate 0 (0.00) 0 0 0 0 0 
Morphine 0 (0.00) 0 0 0 0 0 
Remifentanil 0 (0.00) 0 0 0 0 0 
Droperidol 0 (0.00) 0 0 0 0 0 
*NSAIDs = Non-steroidal anti-inflammatory drugs 
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 Number of sedative agents used in combination 
Thirty-eight dental practitioners answered the question about the number of agents 
used in combination during PSA. Six respondents indicated that they were not aware 
of the combination used by the PSA provider. Table 4.5 presents this data. 
 
Table 4.5 Number of sedative agents used in combination 
Number of agents Dental practices 
n %* 
1 10 31.25 
2 13 40.63 
3 8 25.00 
4 or more 1 3.13 
Respondent unaware 6 - 
Total 38 100.01 
*Percent of dental practices in which the dental practitioner is aware of the combination used 
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 Routes of administration 
Forty-eight dental practitioners answered the question about the route of 
administration of sedative agents. Respondents could select more than one answer 
if applicable to their practice. Oral administration is most common and is used by 25 
(52.08%) PSA providers. Intravenous (22 PSA providers; 45.83%), inhalational (20 
PSA providers; 41.67%), and intramuscular (1 PSA provider; 2.08%) drug 
administration are the other routes used for paediatric dental chair PSA. None of the 
PSA providers administer drugs rectally. These results are broken down into 
professional categories of PSA providers and illustrated in Figure 4.2. 
 
Figure 4.2 Routes of PSA drug administration and the professional category of PSA 
providers 
 
*Professional category of person primarily responsible for administering PSA 
 
4.2.6 Objective 4: Sedation and resuscitation training of PSA providers 
 Sedation training 
Twenty-two dental practitioners indicated that they are primarily responsible for PSA 
administration (Table 4.3), of whom 12 (54.55%) have had sedation training. One 
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respondent indicated that he received 6 years of sedation training in the United 
Kingdom. Thirty-six (81.82%) of 44 dental practitioners indicated that they are 
interested in attending a CPD-accredited sedation course. 
 
 Resuscitation training 
Forty-five respondents answered the questions about resuscitation training, 
membership with SOSPOSA and awareness of PSA guidelines. Of these 
respondents, thirty-eight (84.44%) have attended a Basic Life Support (BLS) course, 
and six (13.33%) have attended APLS or PALS courses. Two (4.44%) respondents 
are members of SOSPOSA. Twelve (26.67%) dental practitioners indicated that they 
are aware of the SASA PSA guidelines (4). 
 
Of the 45 respondents, 20 (44.44%) dental practitioners are primarily responsible for 
administering PSA in their rooms. Eighteen (90%) of them have attended a BLS 
course, two (10%) have attended an APLS or PALS course, four (20%) are aware of 
the SASA PSA guidelines (4), and none are members of SOSPOSA. One 
respondent is a member of The Society for the Advancement of Anaesthesia in 
Dentistry, which is based in the United Kingdom.  
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4.2.7 Objective 5: Adherence to recommended safety standards for prevention 
of adverse events 
 Age groups  
Forty-seven dental practitioners answered the question about the age groups of 
children receiving PSA in their practices. Respondents could select more than one 
age group if applicable to their practice. The 1-5 year and 6-8 year age groups are 
most commonly sedated (76.60% and 74.47% respectively). The 9-12 year age 
group receives PSA in 20 dental practices (42.55%). Two dental practitioners 
perform procedures under PSA in children less than 1 year of age. These results are 
broken down into professional categories of PSA providers and presented in Table 
4.6. 
 
Table 4.6 Ages of children receiving dental chair PSA and the professional category 
of PSA providers 
Age group 
(years) 
Dental 
practices 
n (%) 
PSA provider 
D
ental
 
practitione
r
 
A
naesth
etist
 
M
edical 
practitione
r 
w
ith
 s
edation 
training
 
M
edical 
practitione
r
 
N
ot
 indicated
 
Less than 1 2 (4.26) 1 0 1 0 0 
1-5 36 (76.60) 13 10 12 0 1 
6-8 35 (74.47) 15 7 12 1 0 
9-12 20 (42.55) 13 1 5 0 1 
 
 
 ASA physical status 
Forty-eight respondents indicated the ASA physical status of patients receiving PSA 
in their rooms. All dental practices provide a PSA service to ASA 1 patients, while 17 
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(35.42%) provide PSA to ASA 2 patients. Only 1 dental practitioner provides PSA to 
ASA 3 and 4 patients. 
 
 Pre-sedation assessment and informed consent 
Thirty-nine (82.98%) out of 47 PSA providers document details of the pre-sedation 
assessment. Informed consent for sedation is obtained from the caregiver by 34 
(75.56%) out of 45 PSA providers. 
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 Fasting 
Forty-five dental practitioners indicated their fasting recommendations prior to 
performing procedures under PSA. These results are presented in Table 4.7 with a 
breakdown of sedation modalities administered in these dental practices. According 
to the SASA PSA guidelines (1), the administration of deep sedation or general 
anaesthesia, sedation via the intravenous route, or the co-administration of two or 
more sedative agents necessitates that patients be starved prior to PSA. 
 
Table 4.7 Fasting recommendations by PSA providers with a breakdown into 
sedation modalities that necessitate fasting 
Fasting 
duration 
 
 
Dental 
practices 
n (%) 
Administers 
deep 
sedation or 
GA*? 
Administers 
intravenous 
sedation? 
Administers ≥2 
sedative agents 
in combination? 
YES NO YES NO NA° YES NO NA° 
Children are not 
starved 
12 
(26.67) 0 12 0 12 0 3 5 4 
2 hours 8 (17.78) 2 6 4 4 0 3 3 2 
4 hours 8 (17.78) 1 7 6 1 1 6 0 2 
6 hours 11 (24.44) 1 10 8 3 0 6 1 4 
8 hours 2 (4.44) 1 1 1 1 0 1 0 1 
10 hours or 
longer 
4 
(8.89) 1 3 2 2 0 1 1 2 
Total 45 (100.00) 
According to the SASA PSA guidelines (4), fasting is necessary prior to deep sedation, general 
anaesthesia, intravenous sedation, or the co-administration of 2 or more sedative agents; 
*GA = general anaesthesia; 
°NA = not answered  
62 
 
 Person responsible for patient monitoring 
Forty-six dental practitioners indicated who is responsible for patient monitoring 
during procedures performed under PSA. Table 4.8 presents these results. 
 
Table 4.8 Person responsible for patient monitoring during PSA 
Responsible person Dental practices 
n % 
Dental practitioner* 
 
19 41.30 
Nurse 
 
1 2.17 
Medical practitioner 
 
0 0 
Medical practitioner with 
sedation training 16 34.78 
Anaesthetist 
 
9 19.57 
Other° 
 
1 2.17 
Total 46 99.99 
*The practitioner performing the dental procedure; 
°Combination of a team 
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 Monitoring equipment 
Forty-six dental practitioners indicated the monitoring equipment used during PSA. 
Respondents could select more than one answer if applicable. Table 4.9 presents 
their responses. 
 
Table 4.9 Monitoring equipment used during PSA 
Equipment Dental practices 
n % 
Pulse oximetry 25 54.35 
Non-invasive blood pressure 16 34.78 
Sedation monitoring chart 14 30.43 
ECG 14 30.43 
Capnography 4 8.70 
Praecordial stethoscope 4 8.70 
Thermometer 4 8.70 
None of the above 19 41.30 
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Nineteen (41.30%) dental practitioners indicated that they perform procedures under 
PSA without using any of the listed monitoring equipment. Table 4.10 provides 
further information about these 19 respondents. 
 
Table 4.10 PSA practices of dental practitioners not using any monitoring equipment 
 Number of dental practices 
Primary PSA provider  
Dental practitioner 19 
Depth of sedation  
Minimal 
Moderate 
Deep or general anaesthesia 
19 
3 
0 
Patient age groups (years)  
<1 
1-5 
6-8 
9-12 
1 
13 
15 
12 
ASA status  
1 
2 
3 
4 
19 
6 
1 
1 
Number of drugs used in combination  
1 
2 
3 or more 
Not indicated 
6 
6 
0 
7 
Route of drug administration  
Inhalation 
Oral 
Other routes 
12 
11 
0 
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 Level of consciousness or depth of sedation monitoring 
Forty-five dental practitioners indicated how level of consciousness or depth of 
sedation is monitored in their practice. Respondents could make more than one 
selection if applicable. This data is presented in Table 4.11. 
 
Table 4.11 Modalities used to measure level of consciousness or depth of sedation 
Monitoring tool Dental practices 
n % 
Response to c/t/p* assessed at 
regular time intervals 30 66.67 
Sedation scale 10 22.22 
BIS° 7 15.56 
Response to c/t/p* only when concern 
that patient is too deeply sedated 3 6.67 
None of the above 13 28.89 
*c/t/p = commands/touch/pain; 
°BIS = Bispectral index monitoring 
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 Recovery 
Forty-three dental practitioners responded to the question about having a recovery 
area. Twenty-six (60.47%) have a staffed recovery area in their dental rooms to 
monitor patients prior to discharge. 
 
Forty-four dental practitioners indicated the parameters assessed in their practice 
during recovery and prior to discharge. Respondents could select more than one 
parameter if applicable. Table 4.12 presents this data. 
 
Table 4.12 Parameters assessed during recovery and prior to discharge 
Parameter Dental practices 
n % 
Level of consciousness 42 95.45 
Movement 31 70.45 
Respiration 27 61.36 
Bleeding 27 61.36 
Availability of a responsible 
caregiver 27 61.36 
Pain 25 56.82 
Nausea/vomiting 20 45.45 
Oxygen saturation 17 38.64 
Ability to drink 12 27.27 
Temperature 9 20.45 
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4.2.8 Objective 6: Adherence to recommended safety standards for 
management of adverse events 
 Emergency drugs 
Forty-four dental practitioners indicated the emergency drugs available during PSA 
procedures. Respondents could make more than one selection. Nineteen (43.18%) 
respondents do not keep any of the listed drugs in stock. Flumazenil is stocked by 5 
(15.15%) of the 33 respondents that use midazolam and 1 (10%) of the 10 diazepam 
users. Naloxone is stocked by 1 (20%) of the 5 respondents that use alfentanil and 
none of the fentanyl (2), meperidine (1) and tilidine (1) users. Table 4.13 contains a 
list of recommended emergency drugs to manage adverse sedation events and the 
number of PSA providers who keep the drugs in stock. 
 
Table 4.13 Emergency drugs stocked by PSA providers 
Emergency drug Dental practices 
n % 
Adrenaline 25 56.82 
Atropine 14 31.82 
Succinylcholine 8 18.18 
Flumazenil 6 13.64 
Naloxone 5 11.36 
None of the above 19 43.18 
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 Emergency equipment 
Forty-six dental practitioners indicated the equipment available for management of 
adverse events that may occur during procedures performed under PSA. 
Respondents could make more than one selection. Table 4.14 presents this data. 
 
Table 4.14 Equipment available for management of adverse events 
Equipment Dental practices 
n % 
Oxygen supply 36 78.26 
Face masks 33 71.74 
Bag-valve ventilation device 22 47.83 
OPA’s or NPA’s* 16 34.78 
Intravenous fluids 16 34.78 
Laryngoscope set 14 30.43 
Endotracheal tubes 14 30.43 
Intravenous cannulae 14 30.43 
Glucose testing machine 10 21.74 
Defibrillator 8 17.39 
ETCO₂° monitoring 2 4.35 
None of the above 9 19.57 
*OPA’s or NPA’s = Oropharyngeal airways or nasopharyngeal airways; 
°ETCO₂ = End-tidal carbon dioxide 
 
4.2.9 Objective 7: Occurrence of complications 
The only complication related to dental chair PSA documented by respondents is an 
allergic reaction (not anaphylaxis) experienced in the hands of one PSA provider. 
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4.3 Discussion 
No South African data reporting the proportion of dental practitioners providing PSA 
could be identified. Similarly, little is known about the compliance of dental PSA 
providers with sedation guidelines. Goodchild et al. (47) conducted a study 
examining the use of outpatient dental sedation in the United States and Canada in 
May 2009. Their study is discussed in detail in chapter two of this report and shares 
many similarities with this one in terms of design and information sought. 
 
Of the 213 dental practitioners interviewed, 94 (44.13%) provide paediatric dental 
chair PSA in their practice. This differs from the 75.7% of American and Canadian 
dental practitioners providing sedation as reported by Goodchild et al. (47). The 
discrepancy could partly be explained by the fact that the latter study included 
patients of all ages whereas our study is focused on paediatric patients only. 
 
Deep sedation and general anaesthesia are less common (10.42% and 2.08% of 
dental practices respectively) than minimal and moderate sedation (56.25% and 
52.08% respectively). The distinction in depth is important, as Hoffman et al. (3) 
found a 3.8% complication rate with planned mild to moderate sedation compared to 
9.2% with planned deep sedation (OR: 2.6). Although Goodchild et al. (47) 
structured this question slightly differently, their data about “type(s)” of sedation 
administered can be compared. They found that N₂O (77% of dental practices), 
minimal enteral (57%), moderate enteral (40%), moderate parenteral (22%), deep 
sedation (13%) and general anaesthesia (10%) were administered. The SASA PSA 
guidelines (4) suggest that deep sedation and general anaesthesia should only be 
performed by those with anaesthetic training. In our study, of the five providers of 
deep sedation, the responsible PSA provider is either an anaesthetist (2 dental 
practices), a medical practitioner with sedation training (2 practices), or the dental 
practitioner (1 practice). The latter indicated having 6 years of sedation training in the 
United Kingdom and over 40 years of sedation experience. An anaesthetist is 
responsible in the only dental practice offering dental chair general anaesthesia. 
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Midazolam is the most commonly used agent, used by 68.8% of PSA providers. 
Local anaesthetic agents, paracetamol and non-steroidal anti-inflammatory drugs are 
not considered as sedative agents in this analysis. Nitrous oxide is used in 19 
(39.6%) dental practices providing PSA and is the most common sedative agent 
administered in practices in which the dental practitioner is primarily responsible for 
PSA provision. Although N₂O is generally considered to be safe, any agent can 
depress the patient’s ability to respond normally to airway obstruction once the drug 
depresses the central nervous system (30, 31). Remifentanil, morphine, clonidine, 
chloral hydrate and droperidol are not used in the rooms of any of the respondents. 
Goodchild et al. (47) asked about the class of drugs most commonly used for enteral 
sedation, which was benzodiazepines (89.6%). 
 
In this study three or more agents are combined in 28.13% of dental practices 
providing PSA. The potential for adverse outcomes is significantly increased when 
three or more drugs with sedative properties are combined (4, 20, 29). A critical 
incident analysis carried out on 118 adverse sedation events found drug interactions 
to be the most common (46.3% of cases) contributory cause of such events (2). This 
does not mean that drugs should not be combined, but emphasises the need for 
adequate monitoring and availability of emergency equipment when a combination of 
sedative agents are administered. 
 
The oral route of drug administration is most frequently used in this study (52.08% of 
PSA providers). This requires adherence to safety guidelines, as a sedative has the 
potential to cause respiratory depression regardless of the route of administration 
(17, 29). In a review of paediatric dental sedation adverse effects from closed 
malpractice claims, Chicka et al. (35) found the administration of oral sedation to be 
involved in 10 of 13 sedation claims. Inhalational administration (75% of dental 
practices) was the most common route in the Goodchild et al. (47) study, followed by 
oral administration (69%). 
 
71 
 
The majority of dental practitioners (76.60%) provide PSA to children less than 6 
years of age. This is the age group most vulnerable to the adverse effects 
associated with sedative medication (20, 35, 36). Two dental practitioners perform 
procedures under PSA in children less than 1 year of age. In one of these practices 
PSA is provided by a medical practitioner with sedation training, while the dental 
practitioner is the primary PSA provider in the other practice. The latter does have 
sedation training and is aware of the SASA PSA guidelines (4). 
 
Only 1 dental practitioner provides PSA to ASA 3 and 4 patients. This practitioner is 
the person responsible for administering PSA and provides mild to moderate 
sedation to children between 1 and 8 years of age. This practitioner further indicates 
that he/she does not stock any of the emergency drugs listed in Table 4.13, nor does 
he/she use any of the monitoring equipment listed in Table 4.9. 
 
Malviya et al. (34) reported an increased incidence of adverse events in infants and  
ASA 3 or 4 patients (compared with ASA 1 or 2; p < 0.0001). The SASA PSA 
guidelines (4) suggest that such patients should preferably be sedated in a hospital 
setting and not in a dental practice 
 
Standard anaesthetic fasting guidelines should be applied prior to deep sedation, 
general anaesthesia, or advanced sedation techniques. Fasting is not necessary 
prior to minimal or moderate sedation, or simple sedation techniques. (4) Section 1.5 
of this report describes these techniques in more detail. Three respondents indicated 
that children receive a combination of two sedative agents without being starved 
prior to sedation. Although these children do not receive deep or intravenous 
sedation, the administration of two or more sedative agents (advanced sedation) 
requires that patients be starved prior to sedation (4). The SASA PSA guidelines 
also recommend that children should not fast for unnecessary lengths of time and 
suggest a fasting period of 6 hours for children having formula feeds or solid food. 
Six (13.33%) dental practitioners recommend fasting for 8 hours or longer. Of the six 
practices, none have a blood glucose testing machine available. 
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The SASA PSA guidelines (4) suggest that patient monitoring should be undertaken 
by someone other than the operator. In 41.30% of practices providing PSA, the 
dental practitioner performing the dental procedure is also responsible for patient 
monitoring. 
 
Of the dental practices that provide sedation, 41.30% do not use any form of 
monitoring equipment, 43.18% do not keep any of the recommended emergency 
drugs in stock and 19.57% do not have any emergency equipment available. 
According to the SASA PSA guidelines (4), sedation should only be performed in an 
environment capable of handling emergencies. Inadequate monitoring and 
equipment are among the usual causes of sedation-related adverse events. (4) In 
comparison, 5% of the sample surveyed by Goodchild et al. (47) did not use any 
monitoring equipment and 25% indicated that they did not keep any antidotal drugs 
(e.g. flumazenil and naloxone) in stock. 
 
Pulse oximetry is a minimum requirement for patient monitoring, and the only 
equipment necessary irrespective of the sedation technique (i.e. simple or advanced) 
employed (4). A pulse oximeter is used by 54.35% of sedation providers in this study 
versus 81% in the study by Goodchild et al. (47). 
 
Only one practitioner reported an adverse event. This was an allergic reaction which 
did not lead to major morbidity or mortality. It is possible that respondents may have 
underreported adverse events. As is the case in this study, the patient cohorts in 
most previous studies describing sedation safety and adverse events contained tens 
or hundreds of patients and were statistically underpowered to report on the 
frequency of events that should occur in no more than one in many thousands (2, 18, 
26, 30, 34-37). The Paediatric Research Consortium reported an overall 
complication rate of 5.3% during paediatric sedation and anaesthesia outside the 
operating room. These included a variety of procedures of which only 1.1% were 
dental in nature. (26) 
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The data collection sheet yielded 52 responses according to statistics provided by 
SurveyMonkey™, with not all respondents providing answers to all questions. It is 
difficult to draw any conclusions about omissions being made by any specific group 
of respondents. 
 
A number of dental practitioners volunteered useful information during the initial 
telephone conversation. There are practitioners who would like to offer PSA in their 
rooms, but feel that they first require training to be able to do so. Some practitioners 
make use of the theatre setting as they are of the opinion that dental room sedation 
is too risky. Common problems encountered by dental practitioners are the shortage 
of available theatre time and difficulty booking anaesthetists for dental procedures. 
Some dental practitioners also complained about the reluctance of medical aid 
schemes to pay anaesthetists for dental chair sedation or to cover the extra costs 
associated with performing dental procedures in the theatre setting. 
 
Despite the risks associated with PSA, it is neither realistic nor necessary to restrict 
its provision to anaesthesiologists, who are insufficient in number to cater for the 
ever-increasing need for paediatric PSA (31, 40, 41). 
 
Many facilities do not adhere to recommended safety standards for prevention and 
management of adverse events. Particular areas of concern are the high number of 
practices in which no monitoring equipment, emergency equipment, or emergency 
drugs are available. 
 
4.4 Summary 
This chapter dealt with an analysis of the data collected and a discussion of the 
results according to the objectives of this study. The data presented included the 
proportion of dental practitioners in Gauteng that utilise paediatric dental chair PSA; 
the category of person primarily responsible for administering PSA; the modalities of 
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paediatric sedation administered in dental rooms; sedation and resuscitation training 
of PSA providers; adherence to recommended safety standards for prevention and 
management of adverse effects; and the occurrence of complications. 
 
In the final chapter a summary of the study is presented, along with the limitations, 
recommendations and conclusions of the study. 
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CHAPTER FIVE 
SUMMARY, LIMITATIONS, RECOMMENDATIONS AND CONCLUSIONS 
 
5.1 Introduction 
In this chapter the aim, objectives, study design and results of the study will be 
briefly reviewed. The limitations of the study will be addressed, recommendations for 
clinical practice and further research made, and a conclusion presented. 
 
5.2 Summary of the study 
5.2.1 Aim of the study 
The aim of this study was to determine the proportion of dental practitioners making 
use of paediatric dental chair PSA in Gauteng and to describe paediatric dental chair 
PSA practice, awareness of the 2010 SASA PSA guidelines (4), and adherence to 
the guidelines. 
 
5.2.2 Objectives of the study 
The objectives of the study were to: 
 determine the proportion of dental practitioners in Gauteng that utilise paediatric 
dental chair PSA;  determine the professional category of person primarily responsible for 
administering PSA;  describe the modalities of paediatric sedation administered in dental rooms 
o depth of sedation 
o drugs used 
o number of sedative agents used in combination 
o routes of administration;  determine sedation and resuscitation training of PSA providers; 
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 determine adherence to recommended safety standards for prevention of 
adverse events 
o age groups of children sedated 
o ASA physical status 
o pre-sedation assessment and informed consent 
o fasting 
o person responsible for patient monitoring 
o monitoring equipment 
o level of consciousness or depth of sedation monitoring 
o recovery;  determine adherence to recommended safety standards for management of 
adverse events 
o emergency drugs 
o emergency equipment;  determine the occurrence of complications of PSA. 
 
5.2.3  Summary of the methodology used in the study 
A prospective, contextual, descriptive survey study design was used. Qualified 
dental practitioners who were listed on the SADA website and practising in Gauteng 
formed the population group studied.  It was determined that a minimum of 200 of 
the 1152 Gauteng-based SADA members would be invited to participate in the 
study. This figure (n=200) would be increased following initial data collection if 
necessary, until a minimum of 20 completed data collection sheets were received. 
The sample size was influenced by available resources (financial and time 
constraints) and the scope of the study. A simple random sampling method was 
used. Inclusion and exclusion criteria were defined. 
 
A web-based data collection sheet was designed using SurveyMonkey™. The SASA 
PSA guidelines (4) served as the main reference point for the development of the 
data collection sheet, which assessed items in the following categories: the 
professional category of person responsible for administering PSA; modalities of 
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sedation administered; awareness of the SASA PSA guidelines (4); sedation and 
resuscitation training of the sedationist; patient selection and assessment; 
monitoring; recovery area and discharge; emergency equipment and drugs; and 
complications. The data collection sheet was developed in consultation with three 
experts in the field. 
 
Participants that consented to participate and indicated using paediatric dental chair 
PSA during the initial telephone interview were then sent an email link to the data 
collection sheet. Anonymous data received from completed data collection sheets 
were uploaded onto a database on the SurveyMonkey™ website for analysis. 
Descriptive statistics were used, with support sought from a biostatistician. 
 
5.3 Main findings of the study 
Of the dental practitioners interviewed, 44.13% (95% CI, 0.37-0.51) provided 
paediatric dental chair PSA. The dental practitioner was primarily responsible for 
PSA administration in 45.83% of dental practices, with a medical practitioner with 
sedation training (31.25%), an anaesthetist (20.83%), or a medical practitioner 
without sedation training (2.08%) responsible in the remaining practices. 
 
The modalities of sedation administered varied between dental practices. Minimal 
and moderate sedation (56.25% and 52.08% of dental practices respectively) were 
more widely used than deep sedation and general anaesthesia (10.42% and 2.08% 
respectively). Midazolam was the most commonly used sedative agent (used in 
68.75% of dental practices), followed by N₂O (39.58%). The latter was the most 
common sedative agent administered in practices in which the dental practitioner 
was primarily responsible for PSA provision. More than two-thirds of PSA providers 
administered a combination of two or more sedative agents. The oral route was the 
most common route of administration (52.08% of dental practices), followed by the 
intravenous (45.83%) and inhalational routes (41.67%). 
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Of the dental practitioners responsible for administering PSA, 45.45% did not have 
any sedation training. Although 90% of practitioners had attended a BLS course, 
90% had not attended APLS or PALS courses, and 80% were not aware of the 
SASA PSA guidelines (4). However, most PSA providers (81.82%) were interested 
in attending a CPD-accredited sedation course. 
 
The majority of dental practitioners offered PSA to children in the 1-5 (76.60% of 
dental practices) and 6-8 year old (74.47%) age groups. Children were usually of 
ASA physical status 1 (100% of practices) or 2 (35.42%). Two dental practices 
provided PSA to infants, while one practice provided PSA to ASA 3 and 4 patients. 
Fasting recommendations varied, with some patients being inadequately starved and 
others inappropriately starved for 8 hours or longer. 
 
Many facilities did not adhere to recommended safety standards for prevention and 
management of adverse events. Of the dental practices that provided sedation, 
41.30% did not use any form of monitoring equipment, 43.18% did not keep any of 
the recommended emergency drugs in stock and 19.57% did not have any 
emergency equipment available. In 41.30% of practices the dental practitioner 
performing the dental procedure was also responsible for patient monitoring. There 
were staffed recovery areas to monitor patients prior to discharge in 60.47% of 
practices. 
 
Reported adverse events during dental chair PSA were rare, with no major adverse 
event reported in this study. 
 
5.4 Limitations of the study 
Results from this study should be examined in light of certain limitations. The study 
was contextual and its scope was thus limited to a certain patient population. Results 
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obtained determined the practice standards of dental practitioners in Gauteng and 
may differ from those in the rest of the country. 
 
Dental practitioners who are members of SADA may reflect a more compliant subset 
of practitioners. The response rate to emailed surveys and data collection sheets are 
generally poor, with 55.91% of issued data collection sheets completed and returned 
in this study. Telephone calls preceding issuing of data collection sheets, anonymity, 
confidentiality, a short and concise data collection sheet, and reminder emails were 
methods used to encourage a good response. The response to the email may have 
been better among the more dedicated dental practitioners who comply with safety 
regulations and continuously look to improve their practice. 
 
Certain questions in the data collection sheet were omitted by some respondents, 
with no clear pattern emerging. A possible explanation for some of the omitted 
questions may be that dental practitioners who were not the primary sedation 
provider were unaware of the sedation practices of the anaesthetist or medical 
practitioner. Although anonymity and confidentiality were assured to participants, 
they may have incorrectly answered certain questions for fear of consequences to 
their practice. 
 
This study uses the SASA PSA guidelines (4) as a reference point. Although most 
validated sedation guidelines are similar for the most part, there are minor variations 
among the various guidelines in terms of recommended safety standards. Dental 
practitioners were asked about sedation and resuscitation training, but were not 
asked about the nature or duration of the training received or whether their training 
was up to date. 
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5.5 Recommendations from the study 
5.5.1 Recommendations for clinical practice 
Performing dental procedures in children is often not possible without the aid of PSA, 
which if provided in dental rooms is cost-effective and avoids the extra expenses 
generated by having to utilise operating theatres. However, patient safety should not 
be compromised in any way. 
 
As demonstrated in this study there is an interest among dental practitioners in 
sedation training. Increased emphasis on such training at undergraduate level and 
through postgraduate sedation courses can overcome the need to rely on the limited 
availability of anaesthesiologists. 
 
There is a lack of awareness among PSA providers about the SASA PSA guidelines 
(4). Increasing awareness about the guidelines may improve adherence to 
recommended safety standards. 
 
There is a reluctance of medical aid schemes to cover the costs of anaesthetists 
providing PSA for dental procedures. This contributes to dental practitioners with 
inadequate PSA and resuscitation training being forced to sedate patients. A review 
of such policies by medical aid schemes is needed in the interest of patient safety. 
 
5.5.2 Recommendations for further research 
Should the above recommendations about sedation training and enhanced 
awareness about the SASA PSA guidelines (4) be introduced, it is suggested that 
their impact be followed up. 
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PSA is a field not confined to dentistry. Comparing the findings of this study to 
procedures performed under PSA in other disciplines is a scope for further research. 
 
As PSA-related adverse events during dental procedures are rare, a larger study 
focusing on the incidence of adverse events and contributory causes in a South 
African setting presents a focus for future research, as well as the impact of sedation 
training and the SASA PSA guidelines (4) on such events. 
 
5.6 Conclusion 
Paediatric dental chair PSA is offered by 44.13% of dental practitioners interviewed 
in Gauteng. The modalities of PSA provided vary between dental practices, with 
many facilities not adhering to recommended safety standards. There is an interest 
in sedation training among dental practitioners. 
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APPENDIX 4 
PARTICIPATION INFORMATION LETTER 
 
Dear Colleague 
 
My name is Faizal Bham. I am a registrar in the Department of Anaesthesiology at the Charlotte Maxeke 
Johannesburg Academic Hospital and registered for a Master of Medicine (Anaesthesiology) degree at the 
Faculty of Health Sciences, University of the Witwatersrand. As part of the course requirement, I am expected to 
conduct research under supervision. 
 
I would like to invite you to participate in my research study, which is being conducted in the field of paediatric 
dental chair sedation. I intend determining the proportion of Gauteng-based dental practitioners making use of 
sedation in children and describing current practice. The study involves completing a short web-based survey, 
which should take no longer than 5 minutes to complete. 
 
The study has been approved by the Human Research Ethics Committee (Medical) (HREC) (clearance certificate 
number M120735) and Postgraduate Committee of the University of the Witwatersrand. Your participation is 
voluntary and you may close the survey at any stage should you wish not to complete or submit it. All responses 
will be uploaded anonymously to an electronic database hosted by SurveyMonkey™. Information you provide 
can therefore not be traced back to you and published results will have no identifying data. Your contact number 
was obtained from the list of members and contact numbers available to the public on the South African Dental 
Association (SADA) website. SADA are, however, not involved with this research in any way. 
 
Published results will be made available to all participants. The study may lead to positive changes in the field of 
paediatric procedural sedation and analgesia. A CPD-accredited sedation course, organised by the Department 
of Anaesthesiology, University of the Witwatersrand, will be offered to participants on completion of the study.  
 
To participate, kindly click on the link to the survey at the end of this email. This will imply consent to participate. 
 
Any queries may be directed to me on 082 768 3831 or the Chairman of the HREC, Professor Cleaton-Jones on 
011 717 1234. 
 
Thank you for taking time to read this email. Your participation in the survey will be much appreciated. 
 
Yours sincerely 
Dr F Bham 
 
CLICK on the following link to complete the survey: [LINK] 
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APPENDIX 5 
RANDOMISATION OF SAMPLING FRAME 
Random Order Random Order Random Order Random Order 
266 1 48823 51 91109 101 123214 151 
1531 2 49836 52 91632 102 123367 152 
2628 3 50132 53 92638 103 125621 153 
3343 4 51680 54 92679 104 126127 154 
3833 5 51790 55 93589 105 126842 155 
4639 6 52470 56 93797 106 128028 156 
5542 7 53007 57 94866 107 128544 157 
6257 8 53183 58 95318 108 129568 158 
6557 9 53777 59 96217 109 130224 159 
8804 10 54533 60 96399 110 130419 160 
10259 11 54693 61 97109 111 131345 161 
10850 12 55154 62 97786 112 131677 162 
11473 13 55251 63 98958 113 132682 163 
12194 14 56990 64 99820 114 133463 164 
12844 15 58434 65 99860 115 134006 165 
13775 16 58989 66 99950 116 134816 166 
15130 17 59217 67 101438 117 135328 167 
15749 18 59388 68 101889 118 137653 168 
16121 19 59588 69 102176 119 138405 169 
17712 20 59823 70 102328 120 138741 170 
18471 21 60785 71 103721 121 139376 171 
20284 22 60834 72 104016 122 140229 172 
20720 23 64539 73 104916 123 142313 173 
21051 24 64715 74 104967 124 142896 174 
21873 25 65934 75 107808 125 143032 175 
22645 26 65988 76 109766 126 144541 176 
22990 27 66706 77 110809 127 145137 177 
24011 28 67723 78 111671 128 145195 178 
25250 29 68198 79 112441 129 146400 179 
25475 30 68703 80 112556 130 147161 180 
25481 31 68872 81 112584 131 147757 181 
25747 32 69822 82 113503 132 147773 182 
27606 33 70868 83 113740 133 150374 183 
28560 34 71112 84 113920 134 150384 184 
31031 35 71562 85 113984 135 151330 185 
31775 36 72839 86 114570 136 151407 186 
32631 37 76030 87 114893 137 151792 187 
34692 38 78216 88 115582 138 152425 188 
35088 39 80577 89 115763 139 155588 189 
37498 40 81703 90 117109 140 156330 190 
40078 41 83440 91 117197 141 156513 191 
41127 42 83810 92 117864 142 157699 192 
41616 43 84322 93 118306 143 157730 193 
42330 44 84402 94 119693 144 157880 194 
44252 45 85572 95 120425 145 158071 195 
44610 46 86073 96 120618 146 160092 196 
45314 47 87099 97 120940 147 160138 197 
45883 48 87920 98 121098 148 160900 198 
48669 49 88617 99 122580 149 161117 199 
48670 50 89989 100 122857 150 162967 200 
 
The 1152 members of the sampling frame were randomly allocated numbers from one to one million. The random numbers 
were then arranged from smallest to largest, with the first 200 being selected as the study sample. 
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APPENDIX 6 
REMINDER EMAIL 
 
Dear Colleague 
 
This is a follow-up email to the one sent two weeks ago requesting your participation in a study in the 
field of paediatric dental chair sedation. The value of the study, which is a requirement in my training 
in the field of anaesthesiology, will be enhanced by a good response from prospective participants. 
 
As all responses are received anonymously, there is no way to ascertain which individuals have not 
yet completed the survey. If you have not yet responded, kindly take the time to do so by following the 
link at the bottom of the page. The survey should take no longer than 5 minutes to complete. I would 
like to reiterate that all responses are uploaded anonymously to an electronic database and published 
results will have no identifying data. 
 
If you have already completed the survey, kindly ignore the link at the bottom of the page. I would like 
to thank you for taking the time to participate. Your contribution to my training and to the field of 
paediatric sedation is much appreciated. 
 
Thank you for reading this email. You will not be inconvenienced with any further reminders. 
 
Yours sincerely 
Faizal Bham 
082 768 3831 
 
If you consent to participate, click on the following link: [LINK] 
 
 
